Jos W M Van Der Meer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/57572/publications.pdf

Version: 2024-02-01

628 papers

65,248 citations

126 h-index 1152 229

648 all docs

648 docs citations

648 times ranked

58855 citing authors

g-index

#	Article	IF	CITATIONS
1	The Effect of Dietary Supplementation with n—3 Polyunsaturated Fatty Acids on the Synthesis of Interleukin-1 and Tumor Necrosis Factor by Mononuclear Cells. New England Journal of Medicine, 1989, 320, 265-271.	13.9	1,843
2	How should we define health?. BMJ: British Medical Journal, 2011, 343, d4163-d4163.	2.4	1,632
3	mTOR- and HIF-1α–mediated aerobic glycolysis as metabolic basis for trained immunity. Science, 2014, 345, 1250684.	6.0	1,517
4	Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nature Reviews Drug Discovery, 2012, 11, 633-652.	21.5	1,479
5	Defining trained immunity and its role in health and disease. Nature Reviews Immunology, 2020, 20, 375-388.	10.6	1,345
6	Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science, 2014, 345, 1251086.	6.0	1,338
7	Bacille Calmette-Guà ©rin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 17537-17542.	3.3	1,294
8	Trained Immunity: A Memory for Innate Host Defense. Cell Host and Microbe, 2011, 9, 355-361.	5.1	1,177
9	Dimensional assessment of chronic fatigue syndrome. Journal of Psychosomatic Research, 1994, 38, 383-392.	1.2	1,049
10	Candida albicans Infection Affords Protection against Reinfection via Functional Reprogramming of Monocytes. Cell Host and Microbe, 2012, 12, 223-232.	5.1	926
11	Circulating Interleukin-1 and Tumor Necrosis Factor in Septic Shock and Experimental Endotoxin Fever. Journal of Infectious Diseases, 1990, 161, 79-84.	1.9	755
12	Differential requirement for the activation of the inflamma some for processing and release of IL-1 \hat{l}^2 in monocytes and macrophages. Blood, 2009, 113, 2324-2335.	0.6	714
13	Human Dectin-1 Deficiency and Mucocutaneous Fungal Infections. New England Journal of Medicine, 2009, 361, 1760-1767.	13.9	671
14	Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. Journal of Clinical Investigation, 2006, 116, 1642-1650.	3.9	632
15	Presence of Genetic Variants Among Young Men With Severe COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 663.	3.8	626
16	<i>STAT1</i> Mutations in Autosomal Dominant Chronic Mucocutaneous Candidiasis. New England Journal of Medicine, 2011, 365, 54-61.	13.9	614
17	Chronic fatigue syndrome. Lancet, The, 2006, 367, 346-355.	6.3	604
18	Glutaminolysis and Fumarate Accumulation Integrate Immunometabolic and Epigenetic Programs in Trained Immunity. Cell Metabolism, 2016, 24, 807-819.	7.2	584

#	Article	IF	Citations
19	The role of TNF- $\hat{l}\pm$ in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. Journal of Lipid Research, 2007, 48, 751-762.	2.0	580
20	Cytokine Patterns in Patients After Major Vascular Surgery, Hemorrhagic Shock, and Severe Blunt Trauma Relation with Subsequent Adult Respiratory Distress Syndrome and Multiple Organ Failure. Annals of Surgery, 1993, 218, 769-776.	2.1	575
21	Toll-Like Receptor 2 Suppresses Immunity against <i>Candida albicans</i> through Induction of IL-10 and Regulatory T Cells. Journal of Immunology, 2004, 172, 3712-3718.	0.4	565
22	The Inflammasome-Mediated Caspase-1 Activation Controls Adipocyte Differentiation and Insulin Sensitivity. Cell Metabolism, 2010, 12, 593-605.	7.2	558
23	Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. Nature Genetics, 1999, 22, 178-181.	9.4	511
24	Innate Immunity to Mycobacterium tuberculosis. Clinical Microbiology Reviews, 2002, 15, 294-309.	5.7	511
25	A guiding map for inflammation. Nature Immunology, 2017, 18, 826-831.	7.0	506
26	Oxidized Low-Density Lipoprotein Induces Long-Term Proinflammatory Cytokine Production and Foam Cell Formation via Epigenetic Reprogramming of Monocytes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1731-1738.	1.1	486
27	Update on Meningococcal Disease with Emphasis on Pathogenesis and Clinical Management. Clinical Microbiology Reviews, 2000, 13, 144-166.	5.7	485
28	Metabolic Induction of Trained Immunity through the Mevalonate Pathway. Cell, 2018, 172, 135-146.e9.	13.5	485
29	Long-Lasting Effects of BCG Vaccination on Both Heterologous Th1/Th17 Responses and Innate Trained Immunity. Journal of Innate Immunity, 2014, 6, 152-158.	1.8	478
30	Cognitive behaviour therapy for chronic fatigue syndrome: a multicentre randomised controlled trial. Lancet, The, 2001, 357, 841-847.	6.3	472
31	Treating inflammation by blocking interleukin-1 in humans. Seminars in Immunology, 2013, 25, 469-484.	2.7	471
32	The Role of Tollâ€like Receptor (TLR) 2 and TLR4 in the Host Defense against Disseminated Candidiasis. Journal of Infectious Diseases, 2002, 185, 1483-1489.	1.9	444
33	Immune defence against Candida fungal infections. Nature Reviews Immunology, 2015, 15, 630-642.	10.6	440
34	Hereditary Periodic Fever. New England Journal of Medicine, 2001, 345, 1748-1757.	13.9	428
35	IL- \hat{l}^2 Processing in Host Defense: Beyond the Inflammasomes. PLoS Pathogens, 2010, 6, e1000661.	2.1	427
36	Host and Environmental Factors Influencing Individual Human Cytokine Responses. Cell, 2016, 167, 1111-1124.e13.	13.5	364

#	Article	IF	CITATIONS
37	Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nature Medicine, 2006, 12, 650-656.	15.2	360
38	BCG-induced trained immunity in NK cells: Role for non-specific protection to infection. Clinical Immunology, 2014, 155, 213-219.	1.4	359
39	Hyperimmunoglobulinemia D and Periodic Fever Syndrome. Medicine (United States), 1994, 73, 133-144.	0.4	346
40	Long-Term Follow-Up, Clinical Features, and Quality of Life in a Series of 103 Patients With Hyperimmunoglobulinemia D Syndrome. Medicine (United States), 2008, 87, 301-310.	0.4	344
41	A Prospective Multicenter Study on Fever of Unknown Origin. Medicine (United States), 2007, 86, 26-38.	0.4	321
42	IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3001-3005.	3.3	308
43	NOD2 and Toll-Like Receptors Are Nonredundant Recognition Systems of Mycobacterium tuberculosis. PLoS Pathogens, 2005, 1, e34.	2.1	304
44	The Macrophage Mannose Receptor Induces IL-17 in Response to Candida albicans. Cell Host and Microbe, 2009, 5, 329-340.	5.1	294
45	IL-1 family nomenclature. Nature Immunology, 2010, 11, 973-973.	7.0	294
46	<i>TLR4</i> polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16645-16650.	3.3	293
47	Aspergillus fumigatusEvades Immune Recognition during Germination through Loss of Tollâ€Like Receptorâ€4–Mediated Signal Transduction. Journal of Infectious Diseases, 2003, 188, 320-326.	1.9	290
48	Circulating Cytokines as Mediators of Fever. Clinical Infectious Diseases, 2000, 31, S178-S184.	2.9	283
49	Inhibition of tollâ€ike receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis and Rheumatism, 2007, 56, 2957-2967.	6.7	281
50	Immune Recognition of <i>Candida albicans</i> i>βâ€glucan by Dectinâ€1. Journal of Infectious Diseases, 2007, 196, 1565-1571.	1.9	277
51	Inflammasome-Independent Regulation of IL-1-Family Cytokines. Annual Review of Immunology, 2015, 33, 49-77.	9.5	275
52	A Functional Genomics Approach to Understand Variation in Cytokine Production in Humans. Cell, 2016, 167, 1099-1110.e14.	13.5	275
53	Inflammatory arthritis in caspase 1 gene–deficient mice: Contribution of proteinase 3 to caspase 1–independent production of bioactive interleukinâ€1β. Arthritis and Rheumatism, 2009, 60, 3651-3662.	6.7	274
54	Trained immunity, tolerance, priming and differentiation: distinct immunological processes. Nature Immunology, 2021, 22, 2-6.	7.0	274

#	Article	IF	CITATIONS
55	IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3526-3531.	3.3	273
56	The Effect of Type 2 Diabetes Mellitus on the Presentation and Treatment Response of Pulmonary Tuberculosis. Clinical Infectious Diseases, 2007, 45, 428-435.	2.9	270
57	Antibiotic prescribing in hospitals: a social and behavioural scientific approach. Lancet Infectious Diseases, The, 2010, 10, 167-175.	4.6	265
58	Trained Immunity or Tolerance: Opposing Functional Programs Induced in Human Monocytes after Engagement of Various Pattern Recognition Receptors. Vaccine Journal, 2014, 21, 534-545.	3.2	262
59	Engagement of fatty acids with tollâ€like receptor 2 drives interleukinâ€1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal–induced gouty arthritis. Arthritis and Rheumatism, 2010, 62, 3237-3248.	6.7	259
60	Society's failure to protect a precious resource: antibiotics. Lancet, The, 2011, 378, 369-371.	6.3	259
61	Fever of Unknown Origin (FUO): I. A prospective multicenter study of 167 patients with FUO, using fixed epidemiologic entry criteria. Medicine (United States), 1997, 76, 392-400.	0.4	254
62	Nucleotide-Binding Oligomerization Domain-2 Modulates Specific TLR Pathways for the Induction of Cytokine Release. Journal of Immunology, 2005, 174, 6518-6523.	0.4	248
63	Functional Consequences of Toll-like Receptor 4 Polymorphisms. Molecular Medicine, 2008, 14, 346-352.	1.9	245
64	Does the shape of lipid A determine the interaction of LPS with Toll-like receptors?. Trends in Immunology, 2002, 23, 135-139.	2.9	242
65	Correlation between Proinflammatory Cytokines and Antiinflammatory Mediators and the Severity of Disease in Meningococcal Infections. Journal of Infectious Diseases, 1995, 172, 433-439.	1.9	241
66	Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. Journal of Leukocyte Biology, 2004, 75, 749-755.	1.5	239
67	Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. ELife, 2020, 9, .	2.8	235
68	Haploinsufficiency of the NF-κB1 Subunit p50 in Common Variable Immunodeficiency. American Journal of Human Genetics, 2015, 97, 389-403.	2.6	232
69	Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 29-37.	3.3	230
70	Schnitzler Syndrome: Beyond the Case Reports: Review and Follow-Up of 94 Patients with an Emphasis on Prognosis and Treatment. Seminars in Arthritis and Rheumatism, 2007, 37, 137-148.	1.6	228
71	Reactive oxygen species $\hat{a}\in \hat{b}$ independent activation of the IL- \hat{l} inflammasome in cells from patients with chronic granulomatous disease. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3030-3033.	3.3	226
72	TREM-1: intracellular signaling pathways and interaction with pattern recognition receptors. Journal of Leukocyte Biology, 2013, 93, 209-215.	1.5	215

#	Article	IF	Citations
73	NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. European Journal of Immunology, 2004, 34, 2052-2059.	1.6	214
74	Innate immune memory: towards a better understanding of host defense mechanisms. Current Opinion in Immunology, $2014, 29, 1-7$.	2.4	214
75	The Effect of Two Different Dosages of Intravenous Immunoglobulin on the Incidence of Recurrent Infections in Patients with Primary Hypogammaglobulinemia. Annals of Internal Medicine, 2001, 135, 165.	2.0	213
76	Human TLR10 is an anti-inflammatory pattern-recognition receptor. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4478-84.	3.3	211
77	A guide to immunotherapy for COVID-19. Nature Medicine, 2022, 28, 39-50.	15.2	206
78	Neutralization of IL-18 Reduces Neutrophil Tissue Accumulation and Protects Mice Against Lethal <i>Escherichia coli</i> and <i>Salmonella typhimurium</i> Endotoxemia. Journal of Immunology, 2000, 164, 2644-2649.	0.4	205
79	Increase in prefrontal cortical volume following cognitive behavioural therapy in patients with chronic fatigue syndrome. Brain, 2008, 131, 2172-2180.	3.7	205
80	Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa. JAMA Dermatology, 2016, 152, 52.	2.0	205
81	Modulation of Inflammation and Cytokine Production by Dietary (n-3) Fatty Acids. Journal of Nutrition, 1996, 126, 1515-1533.	1.3	202
82	Induction of circulating tumor necrosis factor (TNF $\hat{1}\pm$) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. Journal of Clinical Immunology, 1988, 8, 426-436.	2.0	201
83	Toll-like receptors as an escape mechanism from the host defense. Trends in Microbiology, 2004, 12, 484-488.	3.5	201
84	Trained Immunity: An Ancient Way of Remembering. Cell Host and Microbe, 2017, 21, 297-300.	5.1	196
85	Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections Journal of Clinical Investigation, 1996, 97, 1366-1372.	3.9	194
86	Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases, 2005, 64, 303-305.	0.5	193
87	Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clinical Pharmacology and Therapeutics, 2004, 75, 476-483.	2.3	190
88	Reflex sympathetic dystrophy of the hand: an excessive inflammatory response?. Pain, 1993, 55, 151-157.	2.0	187
89	In vitro production of IL $1\hat{l}^2$, IL $1\hat{l}^\pm$, TNF and IL 2 in healthy subjects: distribution, effect of cyclooxygenase inhibition and evidence of independent gene regulation. European Journal of Immunology, 1989, 19, 2327-2333.	1.6	183
90	Molecular analysis of MVK mutations and enzymatic activity in hyper-lgD and periodic fever syndrome. European Journal of Human Genetics, 2001, 9, 260-266.	1.4	182

#	Article	IF	CITATIONS
91	A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 694-703.	3.3	182
92	Inflammasome-Independent Modulation of Cytokine Response by Autophagy in Human Cells. PLoS ONE, 2011, 6, e18666.	1.1	182
93	Identifying physical activity patterns in chronic fatigue syndrome using actigraphic assessment. Journal of Psychosomatic Research, 2000, 49, 373-379.	1.2	179
94	Apolipoprotein E knock-out mice are highly susceptible to endotoxemia and Klebsiella pneumoniae infection. Journal of Lipid Research, 1999, 40, 680-685.	2.0	176
95	Differential Cytokine Production and Toll-Like Receptor Signaling Pathways by Candida albicans Blastoconidia and Hyphae. Infection and Immunity, 2005, 73, 7458-7464.	1.0	175
96	Differential Expression of Proinflammatory Cytokines and Their Inhibitors during the Course of Meningococcal Infections. Journal of Infectious Diseases, 1994, 169, 157-161.	1.9	173
97	From the Th1/Th2 Paradigm towards a Toll-Like Receptor/T-Helper Bias. Antimicrobial Agents and Chemotherapy, 2005, 49, 3991-3996.	1.4	173
98	Measurement of immunoreactive interleukin- \hat{l}^2 from human mononuclear cells: Optimization of recovery, intrasubject consistency, and comparison with interleukin- \hat{l}^2 and tumor necrosis factor. Clinical Immunology and Immunopathology, 1988, 49, 424-438.	2.1	172
99	Crohn's disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2. Gut, 2011, 60, 1229-1235.	6.1	172
100	Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing?. Trends in Immunology, 2003, 24, 254-258.	2.9	171
101	The dectin-1/inflammasome pathway is responsible for the induction of protective T-helper 17 responses that discriminate between yeasts and hyphae of <i>Candida albicans</i> Leukocyte Biology, 2011, 90, 357-366.	1.5	169
102	Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer. PLoS Pathogens, 2014, 10, e1004485.	2.1	167
103	Innate immune memory: An evolutionary perspective. Immunological Reviews, 2018, 283, 21-40.	2.8	165
104	Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans. Nature Communications, 2013, 4, 1342.	5 . 8	157
105	Selective Antimicrobial Modulation of Human Microbial Flora: Infection Prevention in Patients with Decreased Host Defense Mechanisms by Selective Elimination of Potentially Pathogenic Bacteria. Journal of Infectious Diseases, 1981, 143, 644-654.	1.9	155
106	The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis and Rheumatism, 2011, 63, 1507-1516.	6.7	154
107	Differences in the synthesis and kinetics of release of interleukin $1\hat{l}_{\pm}$, interleukin $1\hat{l}^2$ and tumor necrosis factor from human mononuclear cells. European Journal of Immunology, 1989, 19, 1531-1536.	1.6	152
108	The influence of gastric acidity on the bio-availability of ketoconazole. Journal of Antimicrobial Chemotherapy, 1980, 6, 552-554.	1.3	150

#	Article	IF	Citations
109	A double-blind, placebo-controlled study of vitamin A and zinc supplementation in persons with tuberculosis in Indonesia: effects on clinical response and nutritional status. American Journal of Clinical Nutrition, 2002, 75, 720-727.	2.2	150
110	Endogenous Interleukin (IL)–1α and ILâ€1β Are Crucial for Host Defense against Disseminated Candidiasis. Journal of Infectious Diseases, 2006, 193, 1419-1426.	1.9	150
111	Dynamic Changes in Pro- and Anti-Inflammatory Cytokine Profiles and Gamma Interferon Receptor Signaling Integrity Correlate with Tuberculosis Disease Activity and Response to Curative Treatment. Infection and Immunity, 2007, 75, 820-829.	1.0	147
112	Trained immunity: A smart way to enhance innate immune defence. Molecular Immunology, 2015, 68, 40-44.	1.0	147
113	Beneficial response to interleukin 1 receptor antagonist in traps. American Journal of Medicine, 2004, 117, 208-210.	0.6	146
114	Gray matter volume reduction in the chronic fatigue syndrome. Neurolmage, 2005, 26, 777-781.	2.1	146
115	Prevalence of xenotropic murine leukaemia virus-related virus in patients with chronic fatigue syndrome in the Netherlands: retrospective analysis of samples from an established cohort. BMJ: British Medical Journal, 2010, 340, c1018-c1018.	2.4	143
116	Cytokines and the response to infection. Journal of Pathology, 1992, 168, 349-356.	2.1	142
117	Mevalonate kinase deficiency. Neurology, 2004, 62, 994-997.	1.5	142
118	On-demand anakinra treatment is effective in mevalonate kinase deficiency. Annals of the Rheumatic Diseases, 2011, 70, 2155-2158.	0.5	142
119	Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2005, 64, 1195-1198.	0.5	141
120	Host–microbe interactions: innate pattern recognition of fungal pathogens. Current Opinion in Microbiology, 2008, 11, 305-312.	2.3	140
121	Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor \hat{l}_{\pm} , and interleukin-6 levels in rheumatoid arthritis Arthritis and Rheumatism, 1993, 36, 1070-1079.	6.7	137
122	Poor Micronutrient Status of Active Pulmonary Tuberculosis Patients in Indonesia. Journal of Nutrition, 2000, 130, 2953-2958.	1.3	136
123	Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases, 2007, 66, 1503-1507.	0.5	136
124	Effect of etanercept and anakinra on inflammatory attacks in the hyper-lgD syndrome: introducing a vaccination provocation model. Netherlands Journal of Medicine, 2005, 63, 260-4.	0.6	134
125	<i>Mycobacterium paratuberculosis</i> i> is recognized by Toll-like receptors and NOD2. Journal of Leukocyte Biology, 2007, 82, 1011-1018.	1.5	133
126	Is a Full Recovery Possible after Cognitive Behavioural Therapy for Chronic Fatigue Syndrome?. Psychotherapy and Psychosomatics, 2007, 76, 171-176.	4.0	132

#	Article	IF	Citations
127	The Role of Hyperuricemia in the Increased Cytokine Production After Lipopolysaccharide Challenge in Neutropenic Mice. Blood, 1997, 89, 577-582.	0.6	129
128	Neural correlates of the chronic fatigue syndrome-an fMRI study. Brain, 2004, 127, 1948-1957.	3.7	126
129	Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. Annals of the Rheumatic Diseases, 2006, 65, 542-544.	0.5	126
130	The inflammasome drives protective Th1 and Th17 cellular responses in disseminated candidiasis. European Journal of Immunology, 2011, 41, 2260-2268.	1.6	126
131	Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. European Cytokine Network, 2006, 17, 29-34.	1.1	125
132	Fever of unknown origin (FUO): II. Diagnostic procedures in a prospective multicenter study of 167 patients. Medicine (United States), 1997, 76, 401-414.	0.4	124
133	Plasma and Whole Blood Exchange in Meningococcal Sepsis. Clinical Infectious Diseases, 1992, 15, 424-430.	2.9	123
134	Pro-inflammatory cytokines in patients with essential hypertension. European Journal of Clinical Investigation, 2001, 31, 31-36.	1.7	121
135	Pro- and anti-inflammatory cytokines in healthy volunteers fed various doses of fish oil for 1 year. European Journal of Clinical Investigation, 1997, 27, 1003-1008.	1.7	120
136	Recognition of fungal pathogens by Toll-like receptors. European Journal of Clinical Microbiology and Infectious Diseases, 2004, 23, 672-6.	1.3	119
137	Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 292, R86-R98.	0.9	118
138	Induction by Toxic-Shock-Syndrome Toxin-1 of a Circulating Tumor Necrosis Factor-Like Substance in Rabbits and of Immunoreactive Tumor Necrosis Factor and Interleukin-1 from Human Mononuclear Cells. Journal of Infectious Diseases, 1988, 158, 1017-1025.	1.9	117
139	Selective Antimicrobial Modulation of the Intestinal Flora of Patients with Acute Nonlymphocytic Leukemia: A Double-Blind, Placebo-Controlled Study. Journal of Infectious Diseases, 1983, 147, 615-623.	1.9	116
140	Interleukin-l Induces Tumor Necrosis Factor (TNF) in Human Peripheral Blood Mononuclear Cells In Vitro and a Circulating TNF-like Activity in Rabbits. Journal of Infectious Diseases, 1990, 162, 215-223.	1.9	116
141	Recognition of Fungal Pathogens by Toll-Like Receptors. Current Pharmaceutical Design, 2006, 12, 4195-4201.	0.9	116
142	Toll-like Receptor 1 Polymorphisms Increase Susceptibility to Candidemia. Journal of Infectious Diseases, 2012, 205, 934-943.	1.9	116
143	The Inflammasome — A Linebacker of Innate Defense. New England Journal of Medicine, 2006, 355, 730-732.	13.9	115
144	Myeloid lineage–restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome. Journal of Allergy and Clinical Immunology, 2015, 135, 561-564.e4.	1.5	115

#	Article	IF	CITATIONS
145	Interleukin-18 induces production of proinflammatory cytokines in mice: no intermediate role for the cytokines of the tumor necrosis factor family and interleukin- $1\hat{l}^2$. European Journal of Immunology, 2000, 30, 3057-3060.	1.6	114
146	An IFN-Î ³ -Independent Proinflammatory Role of IL-18 in Murine Streptococcal Cell Wall Arthritis. Journal of Immunology, 2000, 165, 6553-6558.	0.4	114
147	Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Association with decreased interferon-? production and toll-like receptor 4 expression. Arthritis and Rheumatism, 2003, 48, 1853-1857.	6.7	111
148	The role of interferon-gamma in the increased tuberculosis risk in type 2 diabetes mellitus. European Journal of Clinical Microbiology and Infectious Diseases, 2008, 27, 97-103.	1.3	111
149	Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin $1\hat{l}^2$ by mononuclear cells through a caspase 1-mediated process. Annals of the Rheumatic Diseases, 2009, 68, 273-278.	0.5	111
150	Diabetes mellitus is strongly associated with tuberculosis in Indonesia. International Journal of Tuberculosis and Lung Disease, 2006, 10, 696-700.	0.6	108
151	Decreased Plasma Leptin Concentrations in Tuberculosis Patients Are Associated with Wasting and Inflammation. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 758-763.	1.8	107
152	Non-LPS components of Chlamydia pneumoniae stimulate cytokine production through Toll-like receptor 2-dependent pathways. European Journal of Immunology, 2002, 32, 1188-1195.	1.6	103
153	Elevated plasma levels of the long pentraxin, pentraxin 3, in severe dengue virus infections. Journal of Medical Virology, 2005, 76, 547-552.	2.5	103
154	Application of the ATC/DDD methodology to monitor antibiotic drug use. European Journal of Clinical Microbiology and Infectious Diseases, 1998, 17, 20-24.	1.3	102
155	STAT1 Hyperphosphorylation and Defective IL12R/IL23R Signaling Underlie Defective Immunity in Autosomal Dominant Chronic Mucocutaneous Candidiasis. PLoS ONE, 2011, 6, e29248.	1.1	101
156	<i>MEFV</i> mutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease. Annals of the Rheumatic Diseases, 2014, 73, 455-461.	0.5	101
157	Dietary Fish-Oil Supplementation in Experimental Gram-Negative Infection and in Cerebral Malaria in Mice. Journal of Infectious Diseases, 1992, 165, 898-903.	1.9	100
158	Modulation of Toll-Like Receptor 2 (TLR2) and TLR4 Responses by <i>Aspergillus fumigatus </i> . Infection and Immunity, 2009, 77, 2184-2192.	1.0	100
159	Role of Dectin-2 for Host Defense against Systemic Infection with Candida glabrata. Infection and Immunity, 2014, 82, 1064-1073.	1.0	100
160	Nuclear medicine's role in infection and inflammation. Lancet, The, 1999, 354, 765-770.	6.3	99
161	Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis. Blood, 2003, 102, 3702-3710.	0.6	99
162	Mycobacterium tuberculosis induces IL-17A responses through TLR4 and dectin-1 and is critically dependent on endogenous IL-1. Journal of Leukocyte Biology, 2010, 88, 227-232.	1.5	97

#	Article	IF	Citations
163	Barriers to optimal antibiotic use for community-acquired pneumonia at hospitals: a qualitative study. Quality and Safety in Health Care, 2007, 16, 143-149.	2.5	95
164	Circulating Interleukin-6 Receptor in Patients with Sepsis Syndrome. Journal of Infectious Diseases, 1995, 171, 469-472.	1.9	94
165	The effect of renin–angiotensin system inhibitors on pro―and anti―nflammatory cytokine production. Immunology, 1998, 94, 376-379.	2.0	93
166	Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells. European Journal of Immunology, 2000, 30, 541-549.	1.6	93
167	Two Patients with Cryptococcal Meningitis and Idiopathic CD4 Lymphopenia: Defective Cytokine Production and Reversal by Recombinant Interferon-Â Therapy. Clinical Infectious Diseases, 2004, 39, e83-e87.	2.9	93
168	Aspergillus fumigatus cell wall components differentially modulate host TLR2 and TLR4 responses. Microbes and Infection, 2011, 13, 151-159.	1.0	93
169	The <scp>IL</scp> â€36 receptor pathway regulates <i><scp>A</scp>spergillus fumigatusâ€</i> induced <scp>T</scp> h1 and <scp>T</scp> h17 responses. European Journal of Immunology, 2013, 43, 416-426.	1.6	93
170	Patterns of Proinflammatory Cytokines and Inhibitors during Typhoid Fever. Journal of Infectious Diseases, 1994, 169, 1306-1311.	1.9	91
171	Is physical deconditioning a perpetuating factor in chronic fatigue syndrome? A controlled study on maximal exercise performance and relations with fatigue, impairment and physical activity. Psychological Medicine, 2001, 31, 107-114.	2.7	91
172	Th17 responses and host defense against microorganisms: an overview. BMB Reports, 2009, 42, 776-787.	1.1	91
173	Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome. Annals of the Rheumatic Diseases, 2013, 72, 1634-1638.	0.5	90
174	Immunodeficiency and Genetic Defects of Pattern-Recognition Receptors. New England Journal of Medicine, 2011, 364, 60-70.	13.9	89
175	Convergent evolution in European and Rroma populations reveals pressure exerted by plague on Toll-like receptors. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 2668-2673.	3.3	88
176	Optimizing antimicrobial therapy. A method for antimicrobial drug me evaluation. Journal of Antimicrobial Chemotherapy, 1992, 30, 724-727.	1.3	87
177	Lymphocyte Subsets, Apoptosis, and Cytokines in Patients with Chronic Fatigue Syndrome. Journal of Infectious Diseases, 1996, 173, 460-463.	1.9	87
178	Role of TLR1 and TLR6 in the host defense against disseminated candidiasis. FEMS Immunology and Medical Microbiology, 2008, 52, 118-123.	2.7	87
179	Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 10272-10277.	3.3	87
180	PENTRAXIN 3 AND C-REACTIVE PROTEIN IN SEVERE MENINGOCOCCAL DISEASE. Shock, 2009, 31, 28-32.	1.0	83

#	Article	IF	CITATIONS
181	Skin Microbiome Imbalance in Patients with STAT1/STAT3 Defects Impairs Innate Host Defense Responses. Journal of Innate Immunity, 2014, 6, 253-262.	1.8	83
182	Circulating concentrations of soluble granzyme A and B increase during natural and experimental Plasmodium falciparum infections. Clinical and Experimental Immunology, 2003, 132, 467-472.	1.1	82
183	Guided self-instructions for people with chronic fatigue syndrome: randomised controlled trial. British Journal of Psychiatry, 2008, 193, 340-341.	1.7	82
184	Molecular Analysis of the Mevalonate Kinase Gene in a Cohort of Patients with the Hyper-IgD and Periodic Fever Syndrome: Its Application as a Diagnostic Tool. Annals of Internal Medicine, 2001, 135, 338.	2.0	81
185	Genetic Variation in the Dectin-1/CARD9 Recognition Pathway and Susceptibility to Candidemia. Journal of Infectious Diseases, 2011, 204, 1138-1145.	1.9	80
186	Approach to genetic analysis in the diagnosis of hereditary autoinflammatory syndromes. Rheumatology, 2006, 45, 269-273.	0.9	79
187	Immunoglobulin D enhances the release of tumour necrosis factorâ€Î±, and interleukinâ€Îβ as well as interleukinâ€1 receptor antagonist from human mononuclear cells. Immunology, 1996, 88, 355-362.	2.0	78
188	<i>Candida albicans</i> Dampens Host Defense by Downregulating IL-17 Production. Journal of Immunology, 2010, 185, 2450-2457.	0.4	78
189	Safety and COVID-19 Symptoms in Individuals Recently Vaccinated with BCG: a Retrospective Cohort Study. Cell Reports Medicine, 2020, 1, 100073.	3.3	78
190	Antibiotic use: How to improve it?. International Journal of Medical Microbiology, 2010, 300, 351-356.	1.5	77
191	Functional and morphological monocyte abnormalities in a patient with malakoplakia. American Journal of Medicine, 1998, 105, 74-77.	0.6	76
192	Social Support and the Persistence of Complaints in Chronic Fatigue Syndrome. Psychotherapy and Psychosomatics, 2004, 73, 174-182.	4.0	76
193	Low plasma selenium concentrations, high plasma human immunodeficiency virus load and high interleukin-6 concentrations are risk factors associated with anemia in adults presenting with pulmonary tuberculosis in Zomba district, Malawi. European Journal of Clinical Nutrition, 2005, 59, 526-532.	1.3	76
194	<i>Bartonella quintana</i> Lipopolysaccharide Is a Natural Antagonist of Toll-Like Receptor 4. Infection and Immunity, 2007, 75, 4831-4837.	1.0	76
195	Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia. Nature Communications, 2014, 5, 4675.	5.8	76
196	Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome. Critical Care Medicine, 1996 , 24 , 1196 - 1202 .	0.4	76
197	Transcriptional and inflammasomeâ€mediated pathways for the induction of ILâ€1β production by <i>Mycobacterium tuberculosis</i>). European Journal of Immunology, 2009, 39, 1914-1922.	1.6	75
198	Long-term in vitro and in vivo effects of \hat{l}^3 -irradiated BCG on innate and adaptive immunity. Journal of Leukocyte Biology, 2015, 98, 995-1001.	1.5	74

#	Article	IF	CITATIONS
199	The Frameshift Mutation in Nod2 Results in Unresponsiveness Not Only to Nod2- but Also Nod1-activating Peptidoglycan Agonists. Journal of Biological Chemistry, 2005, 280, 35859-35867.	1.6	73
200	The Candida Th17 response is dependent on mannan- and Â-glucan-induced prostaglandin E2. International Immunology, 2010, 22, 889-895.	1.8	73
201	Autophagy modulates the Mycobacterium tuberculosis-induced cytokine response. Immunology, 2011, 134, 341-348.	2.0	73
202	Pharmacologic Inhibitors of Tumor Necrosis Factor Production Exert Differential Effects in Lethal Endotoxemia and in Infection with Live Microorganisms in Mice. Journal of Infectious Diseases, 1995, 171, 393-399.	1.9	72
203	Influence of genetic variations in TLR4 and TIRAP/Mal on the course of sepsis and pneumonia and cytokine release: an observational study in three cohorts. Critical Care, 2010, 14, R103.	2.5	72
204	Transmission of trained immunity and heterologous resistance to infections across generations. Nature Immunology, 2021, 22, 1382-1390.	7.0	72
205	Bypassing Pathogenâ€Induced Inflammasome Activation for the Regulation of Interleukinâ€1β Production by the Fungal Pathogen <i>Candida albicans</i> . Journal of Infectious Diseases, 2009, 199, 1087-1096.	1.9	70
206	Enhanced interleukin- $1\hat{l}^2$ production of PBMCs from patients with gout after stimulation with Toll-like receptor-2 ligands and urate crystals. Arthritis Research and Therapy, 2012, 14, R158.	1.6	70
207	Engagement of NOD2 has a dual effect on prolLâ \in 1 \hat{l}^2 mRNA transcription and secretion of bioactive lLâ \in 1 \hat{l}^2 . European Journal of Immunology, 2008, 38, 184-191.	1.6	69
208	Comparison of the effects of recombinant interleukin 6 and recombinant interleukin 1 on nonspecific resistance to infection. European Journal of Immunology, 1989, 19, 413-416.	1.6	68
209	Tailored Interventions to Improve Antibiotic Use for Lower Respiratory Tract Infections in Hospitals: A Cluster-Randomized, Controlled Trial. Clinical Infectious Diseases, 2007, 44, 931-941.	2.9	68
210	Circulating Leptin and Adiponectin Concentrations During Tumor Necrosis Factor Blockade in Patients with Active Rheumatoid Arthritis. Journal of Rheumatology, 2009, 36, 724-730.	1.0	68
211	Cytokine Gene Polymorphisms and the Outcome of Invasive Candidiasis: A Prospective Cohort Study. Clinical Infectious Diseases, 2012, 54, 502-510.	2.9	68
212	Erysipelas-like skin lesions associated with Campylobacter jejuni septicemia in patients with hypogammaglobulinemia. European Journal of Clinical Microbiology and Infectious Diseases, 1992, 11, 842-847.	1.3	67
213	The Role of Endogenous Interleukin (IL)–18, ILâ€12, ILâ€1β, and Tumor Necrosis Factor–α in the Production Interferonâ€Î³ Induced byCandida albicansin Human Wholeâ€Blood Cultures. Journal of Infectious Diseases, 2002, 185, 963-970.	of 1.9	67
214	Complement Activation and Complement-Dependent Inflammation by Neisseria meningitidis Are Independent of Lipopolysaccharide. Infection and Immunity, 2004, 72, 3344-3349.	1.0	67
215	Chronic fatigue syndrome: a clinical and laboratory study with a well matched control group. Journal of Internal Medicine, 1995, 237, 499-506.	2.7	66
216	Changes in the Plasma Lipid Profile as a Potential Predictor of Clinical Outcome in Dengue Hemorrhagic Fever. Clinical Infectious Diseases, 2002, 34, 1150-1153.	2.9	66

#	Article	IF	Citations
217	Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolaemia. European Journal of Clinical Investigation, 2004, 34, 94-99.	1.7	66
218	Gene polymorphisms in pattern recognition receptors and susceptibility to idiopathic recurrent vulvovaginal candidiasis. Frontiers in Microbiology, 2014, 5, 483.	1.5	66
219	Recognition of <i>Borrelia burgdorferi </i> by NOD2 Is Central for the Induction of an Inflammatory Reaction. Journal of Infectious Diseases, 2010, 201, 1849-1858.	1.9	64
220	Variable recognition of <i>Candida albicans </i> strains by TLR4 and lectin recognition receptors. Medical Mycology, 2010, 48, 897-903.	0.3	64
221	Understanding human immune function using the resources from the Human Functional Genomics Project. Nature Medicine, 2016, 22, 831-833.	15.2	63
222	Increased susceptibility to systemic candidiasis in interleukin-6 deficient mice 1. Medical Mycology, 1999, 37, 419-426.	0.3	62
223	Role of the dual interaction of fungal pathogens with pattern recognition receptors in the activation and modulation of host defence. Clinical Microbiology and Infection, 2006, 12, 404-409.	2.8	62
224	Inhibition of caspase-1 activation in gram-negative sepsis and experimental endotoxemia. Critical Care, 2011, 15, R27.	2.5	61
225	Neutrophil-Mediated Inhibition of Proinflammatory Cytokine Responses. Journal of Immunology, 2012, 189, 4806-4815.	0.4	61
226	Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19. Journal of Infectious Diseases, 2021, 223, 1322-1333.	1.9	61
227	Interleukin-1 as a mediator of fatigue in disease: a narrative review. Journal of Neuroinflammation, 2017, 14, 16.	3.1	60
228	Effort but not Reward Sensitivity is Altered by Acute Sickness Induced by Experimental Endotoxemia in Humans. Neuropsychopharmacology, 2018, 43, 1107-1118.	2.8	59
229	BACTERIAL LIPOPOLYSACCHARIDE BINDS AND STIMULATES CYTOKINE-PRODUCING CELLS BEFORE NEUTRALIZATION BY ENDOGENOUS LIPOPROTEINS CAN OCCUR. Cytokine, 1998, 10, 766-772.	1.4	58
230	Monomeric IgG in Intravenous Ig Preparations Is a Functional Antagonist of FcγRII and FcγRIIIb. Journal of Immunology, 2004, 173, 332-339.	0.4	58
231	Functional consequences of the Asp299Gly Toll-like receptor-4 polymorphism. Cytokine, 2005, 30, 264-268.	1.4	58
232	Effects of antirheumatic agents on cytokines. Seminars in Arthritis and Rheumatism, 1996, 25, 234-253.	1.6	57
233	Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. International Journal of Tuberculosis and Lung Disease, 2002, 6, 497-502.	0.6	57
234	Reduced production of immunoregulatory cytokines in vitamin A- and zinc-deficient Indonesian infants. European Journal of Clinical Nutrition, 2004, 58, 1498-1504.	1.3	57

#	Article	IF	Citations
235	The role of NLRs and TLRs in the activation of the inflammasome. Expert Opinion on Biological Therapy, 2008, 8, 1867-1872.	1.4	57
236	Severe Candida spp. infections: new insights into natural immunity. International Journal of Antimicrobial Agents, 2010, 36, S58-S62.	1.1	57
237	Effect of Clarithromycin in Inflammatory Markers of Patients with Ventilator-Associated Pneumonia and Sepsis Caused by Gram-Negative Bacteria: Results from a Randomized Clinical Study. Antimicrobial Agents and Chemotherapy, 2012, 56, 3819-3825.	1.4	57
238	Complement plays a central role in <i><scp>C</scp>andida albicans</i> â€induced cytokine production by human <scp>PBMC</scp> s. European Journal of Immunology, 2012, 42, 993-1004.	1.6	57
239	A Salty Taste to Autoimmunity. New England Journal of Medicine, 2013, 368, 2520-2521.	13.9	57
240	<i>Candida albicans</i> Primes TLR Cytokine Responses through a Dectin-1/Raf-1–Mediated Pathway. Journal of Immunology, 2013, 190, 4129-4135.	0.4	57
241	TLR1/TLR2 Heterodimers Play an Important Role in the Recognition of Borrelia Spirochetes. PLoS ONE, 2011, 6, e25998.	1.1	57
242	Compartmentalized Cytokine Responses in Hidradenitis Suppurativa. PLoS ONE, 2015, 10, e0130522.	1.1	57
243	Suspension cultures of mononuclear phagocytes in the Teflon culture bag. Cellular Immunology, 1979, 42, 208-212.	1.4	56
244	Enteroviruses and the Chronic Fatigue Syndrome. Clinical Infectious Diseases, 1994, 19, 860-864.	2.9	56
245	Recombinant Murine Granulocyte Colonyâ€Stimulating Factor Protects against Acute DisseminatedCandida albicansInfection in Nonneutropenic Mice. Journal of Infectious Diseases, 1998, 177, 175-181.	1.9	56
246	Redistribution of vitamin A after iron supplementation in Indonesian infants. American Journal of Clinical Nutrition, 2003, 77, 651-657.	2.2	56
247	Quality of Antibiotic Use for Lower Respiratory Tract Infections at Hospitals: (How) Can We Measure It?. Clinical Infectious Diseases, 2005, 41, 450-460.	2.9	56
248	Interleukin-18 resistance in patients with obesity and type 2 diabetes mellitus. International Journal of Obesity, 2008, 32, 1407-1414.	1.6	56
249	A founder effect in the hyperimmunoglobulinemia D and periodic fever syndrome. American Journal of Medicine, 2003, 114, 148-152.	0.6	55
250	Low prevalence of lactase persistence in Neolithic South-West Europe. European Journal of Human Genetics, 2012, 20, 778-782.	1.4	55
251	Natural course and predicting self-reported improvement in patients with chronic fatigue syndrome with a relatively short illness duration. Journal of Psychosomatic Research, 2002, 53, 749-753.	1.2	54
252	Differential function of the NACHT-LRR (NLR) members Nod1 and Nod2 in arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9017-9022.	3.3	54

#	Article	IF	Citations
253	TREM-1 interaction with the LPS/TLR4 receptor complex. European Cytokine Network, 2011, 22, 11-14.	1.1	54
254	The discriminative capacity of soluble Toll-like receptor (sTLR)2 and sTLR4 in inflammatory diseases. BMC Immunology, 2014, 15, 55.	0.9	54
255	NOD2 3020insC mutation and the pathogenesis of Crohn's disease: impaired IL-1beta production points to a loss-of-function phenotype. Netherlands Journal of Medicine, 2005, 63, 305-8.	0.6	54
256	Selective regulation of intercellular adhesion molecule-1 expression by interleukin-18 and interleukin-12 on human monocytes. Immunology, 2003, 110, 329-334.	2.0	53
257	Human dendritic cells are less potent at killing Candida albicans than both monocytes and macrophages. Microbes and Infection, 2004, 6, 985-989.	1.0	53
258	Crohn's disease patients homozygous for the 3020insC NOD2 mutation have a defective NOD2/TLR4 cross-tolerance to intestinal stimuli. Immunology, 2008, 123, 600-605.	2.0	53
259	Antibiotic use in Dutch hospitals 1991–1996. Journal of Antimicrobial Chemotherapy, 2000, 45, 251-256.	1.3	52
260	The effect of a polynutrient supplement on fatigue and physical activity of patients with chronic fatigue syndrome: a double-blind randomized controlled trial. QJM - Monthly Journal of the Association of Physicians, 2002, 95, 677-683.	0.2	52
261	The Epigenetic Memory of Monocytes and Macrophages as a Novel Drug Target in Atherosclerosis. Clinical Therapeutics, 2015, 37, 914-923.	1.1	52
262	Hyper-Immunoglobulin A in the Hyperimmunoglobulinemia D Syndrome. Vaccine Journal, 2001, 8, 58-61.	2.6	51
263	Concentration-dependency of \hat{l}^2 -lactam-induced filament formation in Gram-negative bacteria. Clinical Microbiology and Infection, 2008, 14, 344-349.	2.8	51
264	IL-18 Serum Concentration Is Markedly Elevated in Acute EBV Infection and Can Serve as a Marker for Disease Severity. Journal of Infectious Diseases, 2012, 206, 197-201.	1.9	51
265	Trained innate immunity and atherosclerosis. Current Opinion in Lipidology, 2013, 24, 487-492.	1.2	51
266	The effects of recombinant interleukin-1 and recombinant tumor necrosis factor on non-specific resistance to infection. Biotherapy (Dordrecht, Netherlands), 1989, 1, 19-25.	0.7	50
267	Autonomic function in patients with chronic fatigue syndrome. Clinical Autonomic Research, 1999, 9, 334-340.	1.4	50
268	CD40/CD40 ligand interactions in the host defense against disseminated Candida albicans infection: the role of macrophage-derived nitric oxide. European Journal of Immunology, 2002, 32, 1455.	1.6	50
269	Receptor Recognition of and Immune Intracellular Pathways for <i>Veillonella parvula</i> Lipopolysaccharide. Vaccine Journal, 2009, 16, 1804-1809.	3.2	50
270	LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors. Atherosclerosis, 1998, 139, 147-152.	0.4	49

#	Article	IF	CITATIONS
271	Differential role of IL-18 and IL-12 in the host defense against disseminatedCandida albicans infection. European Journal of Immunology, 2003, 33, 3409-3417.	1.6	49
272	Fluorine 18 fluorodeoxyglucose positron emission tomography in the diagnosis and follow-up of three patients with vasculitis. American Journal of Medicine, 2004, 116, 50-53.	0.6	49
273	Successful canakinumab treatment identifies IL- \hat{l}^2 as a pivotal mediator in Schnitzler syndrome. Journal of Allergy and Clinical Immunology, 2011, 128, 1352-1354.	1.5	49
274	Restriction of Longâ€term Indwelling Urethral Catheterisation in the Elderly. British Journal of Urology, 1986, 58, 683-688.	0.1	48
275	Implementation of an educational program and an antibiotic order form to optimize quality of antimicrobial drug use in a department of internal medicine. European Journal of Clinical Microbiology and Infectious Diseases, 1997, 16, 904-912.	1.3	48
276	Hemodynamic and neurohumoral responses to head-up tilt in patients with chronic fatigue syndrome. Clinical Autonomic Research, 2002, 12, 273-280.	1.4	48
277	Maternal micronutrient supplementation with zinc and \hat{l}^2 -carotene affects morbidity and immune function of infants during the first 6 months of life. European Journal of Clinical Nutrition, 2010, 64, 1072-1079.	1.3	48
278	Mast Cells Induce Vascular Smooth Muscle Cell Apoptosis via a Toll-Like Receptor 4 Activation Pathway. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 1960-1969.	1.1	48
279	Effectiveness of Long-term Doxycycline Treatment and Cognitive-Behavioral Therapy on Fatigue Severity in Patients with Q Fever Fatigue Syndrome (Qure Study): A Randomized Controlled Trial. Clinical Infectious Diseases, 2017, 64, 998-1005.	2.9	48
280	Is cognitive behaviour therapy for chronic fatigue syndrome also effective for pain symptoms?. Behaviour Research and Therapy, 2007, 45, 2034-2043.	1.6	47
281	Zinc and vitamin A supplementation fails to reduce sputum conversion time in severely malnourished pulmonary tuberculosis patients in Indonesia. Nutrition Journal, 2010, 9, 41.	1.5	47
282	Specific targeting of infectious foci with radioiodinated human recombinant interleukin-1 in an experimental model. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 1249-1255.	2.2	46
283	Optimizing the timing of antimicrobial prophylaxis in surgery: an intervention study. Journal of Antimicrobial Chemotherapy, 1996, 38, 301-308.	1.3	46
284	Role of Interleukin-18 in Host Defense against Disseminated Candida albicans Infection. Infection and Immunity, 2002, 70, 3284-3286.	1.0	46
285	Linkage of autosomal-dominant common variable immunodeficiency to chromosome 4q. European Journal of Human Genetics, 2006, 14, 867-875.	1.4	46
286	Host defence against disseminatedCandida albicansinfection and implications for antifungal immunotherapy. Expert Opinion on Biological Therapy, 2006, 6, 891-903.	1.4	46
287	Redundant role of TLR9 for anti-Candida host defense. Immunobiology, 2008, 213, 613-620.	0.8	46
288	Possible Detrimental Effects of Cognitive Behaviour Therapy for Chronic Fatigue Syndrome. Psychotherapy and Psychosomatics, 2010, 79, 249-256.	4.0	46

#	Article	IF	Citations
289	Respiratory failure elicited by streptococcal septicaemia in patients treated with cytosine arabinoside, and its prevention by penicillin. Infection, 1990, 18, 131-137.	2.3	45
290	Optimising antimicrobial drug use in surgery: an intervention study in a Dutch university hospital. Journal of Antimicrobial Chemotherapy, 1996, 38, 1001-1012.	1.3	45
291	The classical CD14 ⁺⁺ CD16 ^{â^'} monocytes, but not the patrolling CD14 ⁺ CD16 ⁺ monocytes, promote Th17 responses to <i>Candida albicans</i> European Journal of Immunology, 2011, 41, 2915-2924.	1.6	45
292	Association of esophageal candidiasis and squamous cell carcinoma. Medical Mycology Case Reports, 2012, 1, 5-8.	0.7	45
293	TLR2/TLR4-dependent exaggerated cytokine production in hyperimmunoglobulinaemia D and periodic fever syndrome. Rheumatology, 2015, 54, 363-368.	0.9	45
294	The role of interleukin-1 beta in the pathophysiology of Schnitzler's syndrome. Arthritis Research and Therapy, 2015, 17, 187.	1.6	45
295	The Role of Dectin-2 for Host Defense Against Disseminated Candidiasis. Journal of Interferon and Cytokine Research, 2016, 36, 267-276.	0.5	45
296	Disease-specific ex vivo stimulation of whole blood for cytokine production: applications in the study of tuberculosis. Journal of Immunological Methods, 1999, 222, 145-153.	0.6	44
297	Interleukin-6 and Human Immunodeficiency Virus Load, But Not Plasma Leptin Concentration, Predict Anorexia and Wasting in Adults with Pulmonary Tuberculosis in Malawi. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4771-4776.	1.8	44
298	Impact of a maximal exercise test on symptoms and activity in chronic fatigue syndrome. Journal of Psychosomatic Research, 2005, 59, 201-208.	1.2	44
299	Antibiotic stewardship and consumption: findings from a pan-European hospital study. Journal of Antimicrobial Chemotherapy, 2009, 64, 853-860.	1.3	44
300	Selective digestive decontamination in intensive care unit patients. Intensive Care Medicine, 1992, 18, 182-188.	3.9	43
301	Epstein-Barr Virus (EBV) and the Chronic Fatigue Syndrome: Normal Virus Load in Blood and Normal Immunologic Reactivity in the EBV Regression Assay. Clinical Infectious Diseases, 1995, 20, 1390-1392.	2.9	43
302	Chlamydia pneumoniaeStimulates IFN- \hat{l}^3 Synthesis through MyD88-Dependent, TLR2- and TLR4-Independent Induction of IL-18 Release. Journal of Immunology, 2004, 173, 1477-1482.	0.4	43
303	A novel splice variant of FcγRlla: AÂrisk factor for anaphylaxis in patients with hypogammaglobulinemia. Journal of Allergy and Clinical Immunology, 2013, 131, 1408-1416.e5.	1.5	43
304	ATP-Induced IL-1β Specific Secretion: True Under Stringent Conditions. Frontiers in Immunology, 2015, 6, 54.	2.2	43
305	Interleukin-1 in the pathogenesis of fever. European Journal of Clinical Investigation, 1987, 17, 469-474.	1.7	42
306	Sequential therapy with intravenous and oral cephalosporins. Journal of Antimicrobial Chemotherapy, 1994, 33, 169-177.	1.3	42

#	Article	IF	Citations
307	Anti-toxoplasma effect of pyrimethamine, trimethoprim and sulphonamides alone and in combination: implications for therapy. Journal of Antimicrobial Chemotherapy, 1996, 38, 75-80.	1.3	42
308	LethalEscherichia coli andSalmonella typhimurium endotoxemia is mediated through different pathways. European Journal of Immunology, 2001, 31, 2529-2538.	1.6	42
309	Variable expression and treatment of PAPA syndrome. Annals of the Rheumatic Diseases, 2011, 70, 1168-1170.	0.5	42
310	Innate immunity networks during infection withBorrelia burgdorferi. Critical Reviews in Microbiology, 2014, 42, 1-12.	2.7	42
311	Technetium-99m labelled liposomes to image experimental arthritis. Annals of the Rheumatic Diseases, 1997, 56, 369-373.	0.5	41
312	Delay in Administering the First Dose of Antibiotics in Patients Admitted to Hospital with Serious Infections. European Journal of Clinical Microbiology and Infectious Diseases, 1998, 17, 681-684.	1.3	41
313	Duration of Antifungal Treatment and Development of Delayed Complications in Patients with Candidaemia. European Journal of Clinical Microbiology and Infectious Diseases, 2003, 22, 43-48.	1.3	41
314	Familial Mediterranean fever—a not so unusual cause of abdominal pain. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2005, 19, 199-213.	1.0	41
315	Differential role of NK cells against <i>Candida albicans</i> infection in immunocompetent or immunocompromised mice. European Journal of Immunology, 2014, 44, 2405-2414.	1.6	41
316	INTERLEUKIN $1\hat{l}^2$, TUMOUR NECROSIS FACTOR- $\hat{l}\pm$ AND INTERLEUKIN 1 RECEPTOR ANTAGONIST IN NEWLY DIAGNOSED INSULIN-DEPENDENT DIABETES MELLITUS: COMPARISON TO LONG-STANDING DIABETES AND HEALTHY INDIVIDUALS. Cytokine, 1997, 9, 284-287.	1.4	40
317	Familial periodic fever and amyloidosis due to a new mutation in the TNFRSF1A gene. American Journal of Medicine, 2001, 110, 313-316.	0.6	40
318	Cognitive Behaviour Group Therapy for Chronic Fatigue Syndrome: A Non-Randomised Waiting List Controlled Study. Psychotherapy and Psychosomatics, 2005, 74, 218-224.	4.0	40
319	The role of Toll-like receptors and C-type lectins for vaccination against Candida albicans. Vaccine, 2010, 28, 614-622.	1.7	40
320	Indium-111-Labeled Human Nonspecific Immunoglobulin G: A New Radiopharmaceutical for Imaging Infectious and Inflammatory Foci. Clinical Infectious Diseases, 1992, 14, 1110-1118.	2.9	39
321	Modulation of the pro- and anti-inflammatory cytokine balance by amphotericin B. Journal of Antimicrobial Chemotherapy, 1998, 42, 469-474.	1.3	39
322	Towards a role of interleukin-32 in atherosclerosis. Cytokine, 2013, 64, 433-440.	1.4	39
323	Bartonella quintana lipopolysaccharide (LPS): structure and characteristics of a potent TLR4 antagonist for in-vitro and in-vivo applications. Scientific Reports, 2016, 6, 34221.	1.6	39
324	Imaging of infection in rabbits with radioiodinated interleukin-1 (\hat{l}_{\pm} and \hat{l}_{\pm}), its receptor antagonist and a chemotactic peptide: a comparative study. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 347-352.	3.3	38

#	Article	IF	CITATIONS
325	The role of clinical guidelines, policies and stewardship. Journal of Hospital Infection, 2003, 53, 172-176.	1.4	38
326	Improving the Process of Antibiotic Therapy in Daily Practice. Archives of Internal Medicine, 2004, 164, 1206.	4.3	38
327	Novel strategies for the prevention and treatment of <i>Candida </i> infections: the potential of immunotherapy. FEMS Microbiology Reviews, 2010, 34, 1063-1075.	3.9	38
328	<i>Aspergillus fumigatus</i> –Induced IL-22 Is Not Restricted to a Specific Th Cell Subset and Is Dependent on Complement Receptor 3. Journal of Immunology, 2013, 190, 5629-5639.	0.4	38
329	Specific Interferon \hat{l}^3 Detection for the Diagnosis of Previous Q Fever. Clinical Infectious Diseases, 2013, 56, 1742-1751.	2.9	38
330	Student performance of the general physical examination in internal medicine: an observational study. BMC Medical Education, 2014, 14, 73.	1.0	38
331	NFKB1 regulates human NK cell maturation and effector functions. Clinical Immunology, 2017, 175, 99-108.	1.4	38
332	Cost-effectiveness of cognitive behaviour therapy for patients with chronic fatigue syndrome. QJM - Monthly Journal of the Association of Physicians, 2004, 97, 153-161.	0.2	37
333	Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis. Rheumatology, 2008, 47, 1651-1654.	0.9	37
334	Dysregulation of innate immunity: hereditary periodic fever syndromes. British Journal of Haematology, 2009, 144, 279-302.	1.2	37
335	<i>Borrelia</i> species induce inflammasome activation and ILâ€17 production through a caspaseâ€1â€dependent mechanism. European Journal of Immunology, 2011, 41, 172-181.	1.6	37
336	Human genetic susceptibility to <i>Candida</i> infections. Medical Mycology, 2012, 50, 785-794.	0.3	37
337	Location of the gene causing hyperimmunoglobulinemia D and periodic fever syndrome differs from that for familial mediterranean fever. Human Genetics, 1994, 94, 616-620.	1.8	36
338	The uptake mechanisms of inflammation-and infection-localizing agents. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 459-465.	2.2	36
339	Scintigraphic detection of infection and inflammation: new developments with special emphasis on receptor interaction. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 535-546.	3.3	36
340	Defective apoptosis of peripheral-blood lymphocytes in hyper-IgD and periodic fever syndrome. Blood, 2007, 109, 2416-2418.	0.6	36
341	DIFFERENTIAL EFFECTS OF IL-17 PATHWAY IN DISSEMINATED CANDIDIASIS AND ZYMOSAN-INDUCED MULTIPLE ORGAN FAILURE. Shock, 2010, 34, 407-411.	1.0	36
342	Different Patterns of Toll-Like Receptor 2 Polymorphisms in Populations of Various Ethnic and Geographic Origins. Infection and Immunity, 2012, 80, 1917-1922.	1.0	36

#	Article	IF	Citations
343	The effects of dexamethasone and chlorpromazine on tumour necrosis factorâ€α , interleukinâ€1 β , interleukinâ€1 receptor antagonist and interleukinâ€10 in human volunteers. Immunology, 1997, 91, 548-552.	2.0	35
344	Plasma Patterns of Tumor Necrosis Factorâ€Î± (TNF) and TNF Soluble Receptors During Acute Meningococcal Infections and the Effect of Plasma Exchange. Clinical Infectious Diseases, 1998, 26, 918-923.	2.9	35
345	Impaired fibrinolysis in the pathogenesis of dengue hemorrhagic fever. Journal of Medical Virology, 2002, 67, 549-554.	2.5	35
346	Severely impaired IL-12/IL-18/IFNgamma axis in patients with hyper IgE syndrome. European Journal of Clinical Investigation, 2005, 35, 718-721.	1.7	35
347	Defective trained immunity in patients with STAT-1-dependent chronic mucocutaneaous candidiasis. Clinical and Experimental Immunology, 2015, 181, 434-440.	1.1	35
348	Mastâ€cell interleukinâ€1β, neutrophil interleukinâ€17 and epidermal antimicrobial proteins in the neutrophilic urticarial dermatosis in Schnitzler's syndrome. British Journal of Dermatology, 2015, 173, 448-456.	1.4	35
349	Hypothesis: stimulation of trained immunity as adjunctive immunotherapy in cancer. Journal of Leukocyte Biology, 2017, 102, 1323-1332.	1.5	35
350	A SEMI-QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION METHOD FOR MEASUREMENT OF MRNA FOR TNF-α AND IL-1β IN WHOLE BLOOD CULTURES: ITS APPLICATION IN TYPHOID FEVER AND EXENTRIC EXERCISE. Cytokine, 1996, 8, 739-744.	1.4	34
351	Persistence of Salmonellae in Blood and Bone Marrow: Randomized Controlled Trial Comparing Ciprofloxacin and Chloramphenicol Treatments against Enteric Fever. Antimicrobial Agents and Chemotherapy, 2003, 47, 1727-1731.	1.4	34
352	Effect of inflammatory attacks in the classical type hyper-IgD syndrome on immunoglobulin D, cholesterol and parameters of the acute phase response. Journal of Internal Medicine, 2004, 256, 247-253.	2.7	34
353	Nucleotide Oligomerization Domain 2 (Nod2) Is Not Involved in the Pattern Recognition of Candida albicans. Vaccine Journal, 2006, 13, 423-425.	3.2	34
354	Role of Interleukin-23 (IL-23) Receptor Signaling for IL-17 Responses in Human Lyme Disease. Infection and Immunity, 2011, 79, 4681-4687.	1.0	34
355	Technetium-99m labelled hydrazinonicotinamido human non-specific polyclonal immunoglobulin G for detection of infectious foci: a comparison with two other technetium-labelled immunoglobulin preparations. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 414-421.	2.2	33
356	Labelled StealthR liposomes in experimental infection. Nuclear Medicine Communications, 1996, 17, 742-748.	0.5	33
357	ENTEROVIRUS-INDUCED PRODUCTION OF PRO-INFLAMMATORY AND T-HELPER CYTOKINES BY HUMAN LEUKOCYTES. Cytokine, 2000, 12, 1793-1796.	1.4	32
358	Delayed Clearance of Intraabdominal Abscesses Caused by Candida albicansin Tumor Necrosis Factorâ€"αâ€" and Lymphotoxinâ€Î±â€"Deficient Mice. Journal of Infectious Diseases, 2002, 186, 1815-1822.	1.9	32
359	α ⁺ â€Thalassemia Protects against Anemia Associated with Asymptomatic Malaria: Evidence from Communityâ€Based Surveys in Tanzania and Kenya. Journal of Infectious Diseases, 2008, 198, 401-408.	1.9	32
360	Drosomycin-Like Defensin, a Human Homologue of (i>Drosophila melanogaster (i>Drosomycin with Antifungal Activity. Antimicrobial Agents and Chemotherapy, 2008, 52, 1407-1412.	1.4	32

#	Article	IF	Citations
361	A combination of interferon-gamma and interleukin-2 production by Coxiella burnetii-stimulated circulating cells discriminates between chronic Q fever and past Q fever. Clinical Microbiology and Infection, 2014, 20, 642-650.	2.8	32
362	A MONOCLONAL ANTIBODY AGAINST TUMOUR NECROSIS FACTOR-α IMPROVES SURVIVAL IN EXPERIMENTAL MULTIPLE ORGAN DYSFUNCTION SYNDROME. Cytokine, 1998, 10, 904-910.	1.4	31
363	LPS-induced cytokine production and expression of \hat{l}^2 2-integrins and CD14 by peripheral blood mononuclear cells of patients with homozygous familial hypercholesterolemia. Atherosclerosis, 1998, 141, 99-105.	0.4	31
364	Dengue disease severity in Indonesian children: an evaluation of the World Health Organization classification system. BMC Infectious Diseases, 2007, 7, 22.	1.3	31
365	Milder clinical hyperimmunoglobulin E syndrome phenotype is associated with partial interleukin-17 deficiency. Clinical and Experimental Immunology, 2010, 159, 57-64.	1.1	31
366	Interferona $\widehat{\in}\widehat{\mathfrak{f}}^3$ and urine neopterin in attacks of the hyperimmunoglobulinaemia D and periodic fever syndrome. European Journal of Clinical Investigation, 1995, 25, 683-686.	1.7	30
367	Cytokine Inhibition in Patients With Chronic Fatigue Syndrome. Annals of Internal Medicine, 2017, 166, 557.	2.0	30
368	Early and late B-cell developmental impairment in nuclear factor kappa B, subunit 1–mutated common variable immunodeficiency disease. Journal of Allergy and Clinical Immunology, 2017, 139, 349-352.e1.	1.5	30
369	BCG vaccination in health care providers and the protection against COVID-19. Journal of Clinical Investigation, 2021, 131, .	3.9	30
370	Imaging Experimental Intraabdominal Abscesses With 99mTc-PEG Liposomes and 99mTc-HYNIC IgG. Annals of Surgery, 1999, 229, 551-557.	2.1	30
371	Campylobacter jejuni bacteraemia as a cause of recurrent fever in a patient with hypogammaglobulinaemia. Journal of Infection, 1986, 12, 235-239.	1.7	29
372	Dissociation of indium from indium-111-labelled diethylene triamine penta-acetic acid conjugated non-specific polyclonal human immunoglobulin G in inflammatory foci. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 212-219.	2.2	29
373	Pro-inflammatory cytokines in lung and blood during steroid-induced <i>Pneumocystis carinii</i> pneumonia in rats. Journal of Leukocyte Biology, 1996, 60, 710-715.	1.5	29
374	Recombinant Interleukinâ€18 Protects against DisseminatedCandida albicansInfection in Mice. Journal of Infectious Diseases, 2004, 189, 1524-1527.	1.9	29
375	Apolipoprotein-E-deficient mice exhibit an increased susceptibility to disseminated candidiasis. Medical Mycology, 2004, 42, 341-348.	0.3	29
376	MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) IN MENINGOCOCCAL SEPTIC SHOCK AND EXPERIMENTAL HUMAN ENDOTOXEMIA. Shock, 2007, 27, 482-487.	1.0	29
377	The role of microbiology and pharmacy departments in the stewardship of antibiotic prescribing in European hospitals. Journal of Hospital Infection, 2007, 65, 73-81.	1.4	29
378	Association of Tollâ€Like Receptor 4 Asp299Gly and Thr399lle Polymorphisms with Increased Infection Risk in Patients with Advanced HIVâ€1 Infection. Clinical Infectious Diseases, 2010, 51, 242-247.	2.9	29

#	Article	IF	CITATIONS
379	Innate Immunity to Mycobacterium Tuberculosis. Advances in Experimental Medicine and Biology, 2003, 531, 241-247.	0.8	29
380	Prevention of viridans-group streptococcal septicemia in oncohematologic patients: A controlled comparative study on the effect of penicillin G and cotrimoxazole. Annals of Hematology, 1992, 64, 260-265.	0.8	28
381	Hemofiltration in septic patients is not able to alter the plasma concentration of cytokines therapeutically. Intensive Care Medicine, 2000, 26, 1176-1178.	3.9	28
382	Modulation of inflammation by autophagy: consequences for Crohn's disease. Current Opinion in Pharmacology, 2012, 12, 497-502.	1.7	28
383	Ebola Virus Disease has Features of Hemophagocytic Lymphohistiocytosis Syndrome. Frontiers in Medicine, 2015, 2, 4.	1.2	28
384	Elevated Serum Level and Altered Glycosylation of $\hat{l}\pm 1$ -Acid Glycoprotein in Hyperimmunoglobulinemia D and Periodic Fever Syndrome: Evidence for Persistent Inflammation. Clinical Immunology and Immunopathology, 1995, 76, 279-284.	2.1	27
385	F-18-fluorodeoxyglucose positron emission tomography leading to a diagnosis of septic thrombophlebitis of the portal vein: description of a case history and review of the literature. Journal of Internal Medicine, 2004, 255, 419-423.	2.7	27
386	Limited humoral and cellular responses to QÂfever vaccination in older adults with risk factors for chronic Q fever. Journal of Infection, 2013, 67, 565-573.	1.7	27
387	Hematogenous candida vertebral osteomyelitis treated with ketoconazole. Infection, 1982, 10, 290-292.	2.3	26
388	Limited value of acyclovir in the treatment of uncomplicated herpes zoster: A placebo-controlled study. Infection, 1984, 12, 338-341.	2.3	26
389	Selective Antimicrobial Modulation of the Intestinal Microbial Flora for Infection Prevention in Patients with Hematologic Malignancies: Evaluation of Clinical Efficacy and the Value of Surveillance Cultures. Scandinavian Journal of Infectious Diseases, 1986, 18, 153-160.	1.5	26
390	Phospholipase A2 Is a Circulating Mediator in Typhoid Fever. Journal of Infectious Diseases, 1995, 172, 305-308.	1.9	26
391	Proinflammatory Cytokines and Treatment of Disease. Annals of the New York Academy of Sciences, 1998, 856, 243-251.	1.8	26
392	Differential Roles of Interleukin-18 (IL-18) and IL-12 for Induction of Gamma Interferon by Staphylococcal Cell Wall Components and Superantigens. Infection and Immunity, 2001, 69, 5025-5030.	1.0	26
393	Long-term follow-up after cognitive behaviour therapy for chronic fatigue syndrome. Journal of Psychosomatic Research, 2017, 97, 45-51.	1.2	26
394	Lipoprotein(a) Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor Alpha Production by Human Mononuclear Cells. Infection and Immunity, 1998, 66, 2365-2367.	1.0	26
395	Caspase-12 and the Inflammatory Response to Yersinia pestis. PLoS ONE, 2009, 4, e6870.	1.1	26
396	Non-radioactive in situ hybridization for the detection of cytomegalovirus infections. Histochemistry, 1988, 88, 367-373.	1.9	25

#	Article	IF	CITATIONS
397	Clinical and immunological studies in patients with an increased serum IgD level. Journal of Clinical Immunology, 1989, 9, 393-400.	2.0	25
398	Treatment of invasive aspergillosis with itraconazole in a patient with chronic granulomatous disease. Journal of Infection, 1990, 20, 147-150.	1.7	25
399	Cytokine Release in an Ovarian Carcinoma Patient Following Intravenous Administration of Bispecific Antibody OC/TR F(ab')2. Journal of the National Cancer Institute, 1993, 85, 1003-1004.	3.0	25
400	Lipopolysaccharideâ€induced production of tumour necrosis factor and interleukinâ€1 is differentially regulated at the receptor level: the role of CD14â€dependent and CD14â€independent pathways. Immunology, 1998, 94, 340-344.	2.0	25
401	Vitamin A deficiency and other factors associated with severe tuberculosis in Timor and Rote Islands, East Nusa Tenggara Province, Indonesia. European Journal of Clinical Nutrition, 2009, 63, 1130-1135.	1.3	25
402	Prefrontal Structure Varies as a Function of Pain Symptoms in Chronic Fatigue Syndrome. Biological Psychiatry, 2017, 81, 358-365.	0.7	25
403	Regulation of Staphylococcus epidermidis-induced IFN- \hat{I}^3 in whole human blood: the role of endogenous IL-18, IL-12, IL-1, and TNF. Cytokine, 2003, 21, 65-73.	1.4	24
404	The effect of cognitive behaviour therapy for chronic fatigue syndrome on self-reported cognitive impairments and neuropsychological test performance. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 434-436.	0.9	24
405	Continuous administration of PBP-2- and PBP-3-specific \hat{l}^2 -lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis. Journal of Antimicrobial Chemotherapy, 2007, 59, 926-933.	1.3	24
406	Differential susceptibility to lethal endotoxaemia in mice deficient in ILâ€1α, ILâ€1β or ILâ€1 receptor type I. Apmis, 2010, 118, 1000-1007.	0.9	24
407	A comparison of patients with Q fever fatigue syndrome and patients with chronic fatigue syndrome with a focus on inflammatory markers and possible fatigue perpetuating cognitions and behaviour. Journal of Psychosomatic Research, 2015, 79, 295-302.	1.2	24
408	Infectious episodes in severely granulocytopenic patients. Infection, 1979, 7, 171-175.	2.3	23
409	Metastatic breast cancer presenting as fever, rash, and arthritis. Cancer, 1995, 75, 1608-1611.	2.0	23
410	Scintigraphic detection of acute experimental endocarditis with the technetium-99m labelled glycoprotein IIb/IIIa receptor antagonist DMP444. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 392-399.	3.3	23
411	Earlier Initiation of Antibiotic Treatment for Severe Infections After Interventions to Improve the Organization and Specific Guidelines in the Emergency Department. Archives of Internal Medicine, 2000, 160, 1317.	4.3	23
412	Pneumococcal aortitis, report of a case with emphasis on the contribution to diagnosis of positron emission tomography using fluorinated deoxyglucose. Clinical Microbiology and Infection, 2003, 9, 73-76.	2.8	23
413	Mannose binding lectin enhances IL- $\hat{1}^2$ and IL- 10 induction by non-lipopolysaccharide (LPS) components of Neisseria meningitidis. Cytokine, 2004, 28, 59-66.	1.4	23
414	Tissue- and Time-Dependent Upregulation of Cytokine mRNA in a Murine Model for the Multiple Organ Dysfunction Syndrome. Annals of Surgery, 2004, 240, 142-150.	2.1	23

#	Article	IF	CITATIONS
415	Barriers to implementing infection prevention and control guidelines during crises: Experiences of health care professionals. American Journal of Infection Control, 2010, 38, 726-733.	1.1	23
416	Effects of the Histone Deacetylase Inhibitor ITF2357 in Autoinflammatory Syndromes. Molecular Medicine, 2011, 17, 363-368.	1.9	23
417	Circulating Lipoproteins Are a Crucial Component of Host Defense against Invasive Salmonella typhimurium Infection. PLoS ONE, 2009, 4, e4237.	1.1	23
418	Candida-specific interferon-gamma deficiency and toll-like receptor polymorphisms in patients with chronic mucocutaneous candidiasis. Netherlands Journal of Medicine, 2003, 61, 365-9.	0.6	23
419	Acyclovir in severe herpes virus infections. American Journal of Medicine, 1982, 73, 271-274.	0.6	22
420	Cytokine profiles in bronchoalveolar lavage fluid and blood in HIVâ€seropositive patients with Pneumocystis carinii pneumonia. European Journal of Clinical Investigation, 1997, 27, 333-339.	1.7	22
421	Mannoseâ€Binding Lectin Is a Critical Factor in Systemic Complement Activation during Meningococcal Septic Shock. Clinical Infectious Diseases, 2009, 49, 1380-1386.	2.9	22
422	Serum bactericidal activity against <i>Helicobacter pylori</i> in patients with hypogammaglobulinaemia. Clinical and Experimental Immunology, 2009, 156, 434-439.	1.1	22
423	The Qure study: Q fever fatigue syndrome – response to treatment; a randomized placebo-controlled trial. BMC Infectious Diseases, 2013, 13, 157.	1.3	22
424	Th1/Th2 cytokine imbalance in a family with hyper-lgE syndrome. Netherlands Journal of Medicine, 2002, 60, 349-53.	0.6	22
425	Adverse reactions to co-trimoxazole in HIV infection: A reappraisal of the glutathione-hydroxylamine hypothesis. Journal of Antimicrobial Chemotherapy, 1996, 37, 55-60.	1.3	21
426	Human lipoproteins have divergent neutralizing effects on E. coli LPS, N. meningitidis LPS, and complete Gram-negative bacteria. Journal of Lipid Research, 2004, 45, 742-749.	2.0	21
427	Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy. Cytokine, 2005, 30, 72-77.	1.4	21
428	Autophagy Modulates Borrelia burgdorferi-induced Production of Interleukin- $1\hat{l}^2$ (IL- $1\hat{l}^2$). Journal of Biological Chemistry, 2013, 288, 8658-8666.	1.6	21
429	Protective host defense against disseminated candidiasis is impaired in mice expressing human interleukin-37. Frontiers in Microbiology, 2015, 5, 762.	1.5	21
430	Altered interferon-Î ³ response in patients with Q-fever fatigue syndrome. Journal of Infection, 2016, 72, 478-485.	1.7	21
431	Cytokine signatures in chronic fatigue syndrome patients: a Case Control Study and the effect of anakinra treatment. Journal of Translational Medicine, 2017, 15, 267.	1.8	21
432	Multi-omics examination of Q fever fatigue syndrome identifies similarities with chronic fatigue syndrome. Journal of Translational Medicine, 2020, 18, 448.	1.8	21

#	Article	IF	CITATIONS
433	INTERLEUKIN 10 MITIGATES THE DEVELOPMENT OF THE ZYMOSAN-INDUCED MULTIPLE ORGAN DYSFUNCTION SYNDROME IN MICE. Cytokine, 1999, 11, 713-721.	1.4	20
434	Murine Borrelia arthritis is highly dependent on ASC and caspase-1, but independent of NLRP3. Arthritis Research and Therapy, 2012, 14, R247.	1.6	20
435	Bacterial translocation in an experimental model of multiple organ dysfunctions. Journal of Surgical Research, 2013, 183, 686-694.	0.8	20
436	A core physical examination in internal medicine: What should students do and how about their supervisors?. Medical Teacher, 2013, 35, e1472-e1477.	1.0	20
437	Genetic Variation in Pattern Recognition Receptors and Adaptor Proteins Associated With Development of Chronic Q Fever. Journal of Infectious Diseases, 2015, 212, 818-829.	1.9	20
438	Intact interferon- \hat{l}^3 response against Coxiella burnetii by peripheral blood mononuclear cells in chronic Q fever. Clinical Microbiology and Infection, 2017, 23, 209.e9-209.e15.	2.8	20
439	Long-term prognosis, treatment, and outcome of patients with fever of unknown origin in whom no diagnosis was made despite extensive investigation. Medicine (United States), 2018, 97, e11241.	0.4	20
440	Long-term effect of cognitive behavioural therapy and doxycycline treatment for patients with Q fever fatigue syndrome: One-year follow-up of the Qure study. Journal of Psychosomatic Research, 2019, 116, 62-67.	1.2	20
441	Cost of hospital antimicrobial chemotherapy. Pharmaceutisch Weekblad, 1991, 13, 248-253.	0.7	19
442	Cytokine profiles in bronchoalveolar lavage fluid and blood in HIV-seronegative patients with Pneumocystis carinii pneumonia. European Journal of Clinical Investigation, 1996, 26, 159-166.	1.7	19
443	A normal platelet count at admission in acute meningococcal disease does not exclude a fulminant course. Intensive Care Medicine, 1998, 24, 157-161.	3.9	19
444	Proinflammatory Cytokines in the Treatment of Bacterial and Fungal Infections. BioDrugs, 2004, 18, 9-22.	2.2	19
445	Candida albicans Releases Soluble Factors That Potentiate Cytokine Production by Human Cells through a Protease-Activated Receptor 1- and 2-Independent Pathway. Infection and Immunity, 2010, 78, 393-399.	1.0	19
446	The Evolutionary History of TLR4 Polymorphisms in Europe. Journal of Innate Immunity, 2012, 4, 168-175.	1.8	19
447	Immunotherapy with G-CSF in patients with chronic mucocutaneous candidiasis. Immunology Letters, 2015, 167, 54-56.	1.1	19
448	Hair and salivary cortisol in a cohort of women with chronic fatigue syndrome. Hormones and Behavior, 2018, 103, 1-6.	1.0	19
449	Circulating and Ex Vivo Production of Pyrogenic Cytokines and Interleukin-1 Receptor Antagonist in 123 Patients with Fever of Unknown Origin. Journal of Infectious Diseases, 1997, 175, 191-194.	1.9	18
450	Fasâ€FasL Interactions Modulate Host Defense against SystemicCandida albicansInfection. Journal of Infectious Diseases, 1999, 180, 1648-1655.	1.9	18

#	Article	IF	CITATIONS
451	LPS-Induced Release of IL- $1\hat{l}^2$, IL- 1 Ra, IL- 6 , and TNF- \hat{l} ±in Whole Blood from Patients with Familial Hypercholesterolemia: No Effect of Cholesterol-Lowering Treatment. Journal of Interferon and Cytokine Research, 2006, 26, 101-107.	0.5	18
452	Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura. Vox Sanguinis, 2011, 101, 138-146.	0.7	18
453	Risk of infections in patients with gout: a population-based cohort study. Scientific Reports, 2017, 7, 1429.	1.6	18
454	Increased interleukin- $\hat{\Pi}^{\pm}$ and interleukin- $\hat{\Pi}^{2}$ production by macrophages of low-density lipoprotein receptor knock-out mice stimulated with lipopolysaccharide is CD11c/CD18-receptor mediated. Immunology, 1998, 95, 466.	2.0	18
455	Chlorpromazine down-regulates tumor necrosis factor-alpha and attenuates experimental multiple organ dysfunction syndrome in mice. Critical Care Medicine, 1998, 26, 1244-1250.	0.4	18
456	Development of a sensitive ELISA for the quantification of human tumour necrosis factor-alpha using 4 polyclonal antibodies. European Cytokine Network, 2005, 16, 215-22.	1.1	18
457	Anakinra for the inflammatory complications of chronic granulomatous disease. Netherlands Journal of Medicine, 2011, 69, 95.	0.6	18
458	Present Status of the Management of Patients with Defective Phagocyte Function. Clinical Infectious Diseases, 1984, 6, 107-121.	2.9	17
459	Infusion of Lipoproteins into Volunteers Enhances the Growth of Candida albicans. Clinical Infectious Diseases, 1999, 28, 1148-1151.	2.9	17
460	In Vivo Efficacy of Trovafloxacin against Bacteroides fragilis in Mixed Infection with either Escherichia coli or a Vancomycin-Resistant Strain of Enterococcus faecium in an Established-Abscess Murine Model. Antimicrobial Agents and Chemotherapy, 2001, 45, 1394-1401.	1.4	17
461	HLA-DRB1*12 is associated with protection against complicated typhoid fever, independent of tumour necrosis factor α. International Journal of Immunogenetics, 2002, 29, 297-300.	1.2	17
462	Serum amyloid A serum concentrations and genotype do not explain low incidence of amyloidosis in Hyper-IgD syndrome. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2005, 12, 115-119.	1.4	17
463	Lovastatin inhibits formation of AA amyloid. Journal of Leukocyte Biology, 2008, 83, 1295-1299.	1.5	17
464	Role of autophagy genetic variants for the risk of Candida infections. Medical Mycology, 2014, 52, 333-341.	0.3	17
465	Adaptation and memory in innate immunity. Seminars in Immunology, 2016, 28, 317-318.	2.7	17
466	A possible role for mitochondrial-derived peptides humanin and MOTS-c in patients with Q fever fatigue syndrome and chronic fatigue syndrome. Journal of Translational Medicine, 2019, 17, 157.	1.8	17
467	REGULATION OF THE PRODUCTION OF PRO-INFLAMMATORY CYTOKINES AND ANTAGONISTS DURING CHEMOTHERAPY-INDUCED NEUTROPENIA IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES. Cytokine, 1997, 9, 702-710.	1.4	16
468	Both TLR2 and TLR4 are involved in the recognition of Candida albicans. Reply to "TLR2, but not TLR4, triggers cytokine production by murine cells in response to Candida albicans yeasts and hyphae―by Gil and Gozalbo, Microbes and Infection 8 (2006) 2823–2824. Microbes and Infection, 2006, 8, 2821-2822.	1.0	16

#	Article	IF	CITATIONS
469	The Effect of Acclydine in Chronic Fatigue Syndrome: A Randomized Controlled Trial. PLOS Clinical Trials, 2007, 2, e19.	3.5	16
470	Cathepsin D activity protects against development of type AA amyloid fibrils. European Journal of Clinical Investigation, 2009, 39, 412-416.	1.7	16
471	Cytokine production from stimulated whole blood cultures inÂrheumatoid arthritis patients treated withÂvarious TNF blocking agents. European Cytokine Network, 2009, 20, 88-93.	1.1	16
472	XMRV and CFSâ€"the sad end of a story. Lancet, The, 2012, 379, e27-e28.	6.3	16
473	Antiâ€ <scp>SSA</scp> antibodies are present in immunoglobulin preparations. Transfusion, 2015, 55, 832-837.	0.8	16
474	Observable phenomena that reveal medical students' clinical reasoning ability during expert assessment of their history taking: a qualitative study. BMC Medical Education, 2017, 17, 147.	1.0	16
475	CSF concentrations of ketoconazole. Journal of Antimicrobial Chemotherapy, 1980, 6, 681-681.	1.3	15
476	Thein vivo andin vitro effects of interleukin-1 and tumor necrosis factor on murine cytomegalovirus infection. Biotherapy (Dordrecht, Netherlands), 1989, 1, 227-231.	0.7	15
477	Natural course of symptoms in Cambodia veterans: a follow-up study. Psychological Medicine, 2001, 31, 331-338.	2.7	15
478	Native LDL potentiate TNFî± and IL-8 production by human mononuclear cells. Journal of Lipid Research, 2002, 43, 1065-1071.	2.0	15
479	The Changing Burden of Infectious Disease in Europe. Science Translational Medicine, 2011, 3, 103cm30.	5.8	15
480	Deficient Candida-Specific T-Helper 17 Response During Sepsis. Journal of Infectious Diseases, 2012, 206, 1798-1802.	1.9	15
481	Resistance to selective decontamination: the jury is still out. Lancet Infectious Diseases, The, 2013, 13, 282-283.	4.6	15
482	Evolution of cytokine production capacity in ancient and modern European populations. ELife, 2021, 10,	2.8	15
483	Hypoglycaemia downregulates endotoxin-induced production of tumour necrosis factor- \hat{l}_{\pm} , but does not affect IL- $1\hat{l}^2$, IL-6, or IL-10. Cytokine, 2003, 22, 71-76.	1.4	14
484	Fever of unknown origin: prospective comparison of diagnostic value of 18F-FDG PET and 111In-granulocyte scintigraphy. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1342-1343.	3.3	14
485	Neisseria meningitidis lipid A mutant LPSs function as LPS antagonists in humans by inhibiting TLR 4-dependent cytokine production. Innate Immunity, 2011, 17, 517-525.	1.1	14
486	Primary immunodeficiencies of pattern recognition receptors. Journal of Internal Medicine, 2012, 272, 517-527.	2.7	14

#	Article	IF	CITATIONS
487	The infectious disease challenges of our time. Frontiers in Public Health, 2013, 1, 7.	1.3	14
488	Central delivery of iodine-125–labeled cetuximab, etanercept and anakinra after perispinal injection in rats: possible implications for treating Alzheimer's disease. Alzheimer's Research and Therapy, 2015, 7, 70.	3.0	14
489	Autoimmunity and B-cell dyscrasia in acute and chronic Q fever: A review of the literature. European Journal of Internal Medicine, 2018, 54, 6-12.	1.0	14
490	Chronic yersiniosis due to defects in the TLR5 and NOD2 recognition pathways. Netherlands Journal of Medicine, 2010, 68, 310-5.	0.6	14
491	Chronic intraperitoneal infusion of low doses of tumor necrosis factor \hat{l}_{\pm} in rats induces a reduction in plasma triglyceride levels. Cytokine, 1992, 4, 561-567.	1.4	13
492	Interleukin-18 does not modulate the acute-phase response. Journal of Endotoxin Research, 2005, 11, 85-88.	2.5	13
493	Role of NOD1 polymorphism in susceptibility and clinical progression of rheumatoid arthritis. Rheumatology, 2013, 52, 806-814.	0.9	13
494	Antimicrobial innovation: combining commitment, creativity and coherence. Nature Reviews Drug Discovery, 2014, 13, 709-710.	21.5	13
495	Postural orthostatic tachycardia is not a useful diagnostic marker for chronic fatigue syndrome. Journal of Internal Medicine, 2017, 281, 179-188.	2.7	13
496	Branhamella catarrhalis septicaemia in a granulocytopenic patient. Infection, 1984, 12, 208-209.	2.3	12
497	The influence of culture conditions and serum lipids on interleukin-1 production by human monocytes. Journal of Immunological Methods, 1988, 108, 19-26.	0.6	12
498	Critical aneurysmal dilatation of the thoracic aorta in young adolescents with variant hyperimmunoglobulin E syndrome. Journal of Internal Medicine, 2006, 259, 615-618.	2.7	12
499	AL amyloidosis enhances development of amyloid A amyloidosis. British Journal of Dermatology, 2007, 156, 748-749.	1.4	12
500	High variability of TLR4 gene in different ethnic groups in Iran. Innate Immunity, 2012, 18, 492-502.	1.1	12
501	A controversial consensus – comment on article by Broderick <i>et al</i> . Journal of Internal Medicine, 2012, 271, 29-31.	2.7	12
502	Carbon: No silver bullet. Science, 2014, 345, 1130-1130.	6.0	12
503	Specific in vitro interferon-gamma and IL-2 production as biomarkers during treatment of chronic Q fever. Frontiers in Microbiology, 2015, 6, 93.	1.5	12
504	The challenge of autoinflammatory syndromes: with an emphasis on hyper-lgD syndrome. Rheumatology, 2016, 55, ii23-ii29.	0.9	12

#	Article	IF	CITATIONS
505	High-Mobility Group Nucleosome-Binding Protein 1 as Endogenous Ligand Induces Innate Immune Tolerance in a TLR4-Sirtuin-1 Dependent Manner in Human Blood Peripheral Mononuclear Cells. Frontiers in Immunology, 2018, 9, 526.	2.2	12
506	The Janus face of Bartonella quintana recognition by Toll-like receptors (TLRs): a review. European Cytokine Network, 2008, 19, 113-8.	1.1	12
507	The Effect of Ondansetron, a 5-HT3Receptor Antagonist, in Chronic Fatigue Syndrome. Journal of Clinical Psychiatry, 2010, 71, 528-533.	1.1	12
508	Increased voluntary exercise in mice deficient for tumour necrosis factor-? and lymphotoxin-?. European Journal of Clinical Investigation, 2007, 37, 737-741.	1.7	11
509	Blocking IL- $1\hat{l}^2$ to slow down progression of ALS?. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12741-12742.	3.3	11
510	Comment on "Detection of an Infectious Retrovirus, XMRV, in Blood Cells of Patients with Chronic Fatigue Syndrome― Science, 2010, 328, 825-825.	6.0	11
511	Y-Chromosome Analysis in Individuals Bearing the Basarab Name of the First Dynasty of Wallachian Kings. PLoS ONE, 2012, 7, e41803.	1.1	11
512	The long wait for a breakthrough in chronic fatigue syndrome. BMJ, The, 2015, 350, h2087-h2087.	3.0	11
513	Fatigue Is Associated With Altered Monitoring and Preparation of Physical Effort in Patients With Chronic Fatigue Syndrome. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 392-404.	1.1	11
514	Bacterial arthritis caused by mycobacterium terrae. Infection, 1981, 9, 204-207.	2.3	10
515	Interleukin-1 and related pro-inflammatory cytokines in the treatment of bacterial infections in neutropenic and non-neutropenic animals. Biotherapy (Dordrecht, Netherlands), 1994, 7, 161-167.	0.7	10
516	Increasing Cytotoxic Activity and Production of Reactive Oxygen and Nitrogen Intermediates by Peritoneal Macrophages During the Development of Multiple Organ Dysfunction Syndrome in Mice. Scandinavian Journal of Immunology, 1996, 44, 361-368.	1.3	10
517	The Role of Post-Traumatic Stress Disorder Symptoms in Fatigued Cambodia Veterans. Military Medicine, 2002, 167, 790-794.	0.4	10
518	Public health implications of using various case definitions in The Netherlands during the worldwide SARS outbreak. Clinical Microbiology and Infection, 2006, 12, 1214-1220.	2.8	10
519	Tryptophan depletion in chronic fatigue syndrome, a pilot cross-over study. BMC Research Notes, 2014, 7, 650.	0.6	10
520	The Loss of Functional Caspase-12 in Europe Is a Pre-Neolithic Event. PLoS ONE, 2012, 7, e37022.	1.1	10
521	Investigating neural mechanisms of change of cognitive behavioural therapy for chronic fatigue syndrome: a randomized controlled trial. BMC Psychiatry, 2015, 15, 144.	1.1	9
522	Diagnostic yield of FDG-PET/CT in fever of unknown origin: a systematic review, meta-analysis, and Delphi exercise. Clinical Radiology, 2018, 73, 588-589.	0.5	9

#	Article	IF	CITATIONS
523	Cytokine profiles in patients with Q fever fatigue syndrome. Journal of Infection, 2019, 78, 349-357.	1.7	9
524	Reply to: â€~Lack of evidence for intergenerational inheritance of immune resistance to infections'. Nature Immunology, 2022, 23, 208-209.	7.0	9
525	Persistence of full-length caspase-12 and its relation to malaria in West and Central African populations. European Cytokine Network, 2010, 21, 77-83.	1.1	9
526	Shifting the Immune Memory Paradigm: Trained Immunity in Viral Infections. Annual Review of Virology, 2022, 9, 469-489.	3.0	9
527	Meningococcal pericarditis in the absence of meningitis. Infection, 1987, 15, 109-110.	2.3	8
528	Statistical analysis of fever interval data. European Journal of Clinical Investigation, 1989, 19, 154-158.	1.7	8
529	Treatment of Intra-Abdominal Abscesses Caused by Candida albicans with Antifungal Agents and Recombinant Murine Granulocyte Colony-Stimulating Factor. Antimicrobial Agents and Chemotherapy, 2003, 47, 3688-3693.	1.4	8
530	Pathophysiology of in-vitro induced filaments, spheroplasts and rod-shaped bacteria in neutropenic mice. Clinical Microbiology and Infection, 2006, 12, 1105-1111.	2.8	8
531	Recognition of fungal pathogens by Toll-like receptors. , 2007, , 259-272.		8
532	Influence of innate cytokine production capacity on clinical manifestation and severity of pediatric meningococcal disease. Critical Care Medicine, 2009, 37, 2812-2818.	0.4	8
533	Interferon-Î ³ and CXCL10 responses related to complaints in patients with Q fever fatigue syndrome. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1385-1391.	1.3	8
534	The effect of salicylates on insulin sensitivity. Journal of Clinical Investigation, 2001, 108, 1723-1724.	3.9	8
535	Feasibility of an antibiotic order form. First experience in the department of internal medicine of a university hospital. International Journal of Clinical Pharmacy, 1996, 18, 137-141.	1.4	7
536	TNFα AND IL-1β EXERT NO DIRECT VASOACTIVITY IN HUMAN ISOLATED RESISTANCE ARTERIES. Cytokine, 2002, 20, 244-246.	1.4	7
537	Comment on: Schnitzlers syndrome exacerbation after anti-TNF treatment. Rheumatology, 2007, 46, 1741-1741.	0.9	7
538	Defects of pattern recognition: primary immunodeficiencies of the innate immune system. Current Opinion in Pharmacology, 2011, 11, 412-422.	1.7	7
539	Variation in Genes of \hat{l}^2 -glucan Recognition Pathway and Susceptibility to Opportunistic Infections in HIV-Positive Patients. Immunological Investigations, 2011, 40, 735-750.	1.0	7
540	Diagnosis of Coxiella burnetii Infection: Comparison of a Whole Blood Interferon-Gamma Production Assay and a Coxiella ELISPOT. PLoS ONE, 2014, 9, e103749.	1,1	7

#	Article	IF	CITATIONS
541	Immunogenicity of the Q fever skin test. Journal of Infection, 2014, 69, 161-164.	1.7	7
542	Cytokine inhibition in chronic fatigue syndrome patients: study protocol for a randomized controlled trial. Trials, 2015, 16, 439.	0.7	7
543	Immune recognition of putative alien microbial structures: Host–pathogen interactions in the age of space travel. PLoS Pathogens, 2020, 16, e1008153.	2.1	7
544	Inhibition of Plasmodium berghei Liver Schizont Development and Reduction of Cytokine Production Capacity in Rats by Dietary Fish Oil Supplementation. American Journal of Tropical Medicine and Hygiene, 1995, 53, 206-210.	0.6	7
545	Prolonged bleeding time during azlocillin therapy. Journal of Antimicrobial Chemotherapy, 1980, 6, 554-556.	1.3	6
546	Pharmacokinetics of vibunazole (BAY n 7133) administered orally to healthy subjects. Journal of Antimicrobial Chemotherapy, 1985, 16, 75-79.	1.3	6
547	Is aciclovir prophylaxis necessary after bone marrow transplantation?. Infection, 1986, 14, 122-124.	2.3	6
548	Immunomodulation by n-3 polyunsaturated fatty acids. Trends in Immunology, 1999, 20, 103.	7.5	6
549	Chronic fatigue syndrome and myalgic encephalomyelitis. Lancet, The, 2002, 359, 1699.	6.3	6
550	Polymorphism in innate immunity genes and susceptibility to recurrent vulvovaginal candidiasis. Journal De Mycologie Medicale, 2009, 19, 191-196.	0.7	6
551	Translational Medicine Policy Issues in Infectious Disease. Science Translational Medicine, 2010, 2, 14cm2.	5 . 8	6
552	Immunologic defects in severe mucocutaneous HSV-2 infections: Response to IFN-Î ³ therapy. Journal of Allergy and Clinical Immunology, 2016, 138, 895-898.	1.5	6
553	Metabolome of chronic fatigue syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E910-E910.	3.3	6
554	Mediation analysis shows that a decline in self-efficacy mediates the increase in fatigue severity following an initial positive response to cognitive behavioural therapy in Q fever fatigue syndrome. Journal of Psychosomatic Research, 2019, 127, 109841.	1.2	6
555	Micronutrient Deficiency and Supplementation in Indonesian Infants. Advances in Experimental Medicine and Biology, 2003, 531, 369-377.	0.8	6
556	Decreased natural killer cell activity in late-onset hypogammaglobulinaemia. Clinical Science, 1990, 78, 133-137.	1.8	5
557	Acute Renal Failure Associated with Paracetamol digestion in an Alcoholic Patient. Nephron, 1994, 67, 483-485.	0.9	5
558	Viral Antibodies in Chronic Fatigue Syndrome. Clinical Infectious Diseases, 1995, 21, 708-709.	2.9	5

#	Article	IF	Citations
559	Control Measures Used during Lymphogranuloma Venereum Outbreak, Europe. Emerging Infectious Diseases, 2008, 14, 573-578.	2.0	5
560	Association of Mal/TIRAP S180L variant polymorphism with decreased infection risk in patients with advanced HIV-1 infection. Cytokine, 2012, 60, 104-107.	1.4	5
561	Cytokine Production Assays Reveal Discriminatory Immune Defects in Adults with Recurrent Infections and Noninfectious Inflammation. Vaccine Journal, 2014, 21, 1061-1069.	3.2	5
562	30Âyears hidsâ€"Travels between bedside and bench. Temperature, 2015, 2, 1-7.	1.7	5
563	Assessing and regulating homeopathic products. Journal of Internal Medicine, 2017, 282, 563-565.	2.7	5
564	Long-Lasting Transcriptional Changes in Circulating Monocytes of Acute Q Fever Patients. Open Forum Infectious Diseases, 2019, 6 , .	0.4	5
565	Globalization of Traditional Chinese Medicine: what are the issues for ensuring evidenceâ€based diagnosis and therapy?. Journal of Internal Medicine, 2020, 287, 210-213.	2.7	5
566	Binding and degradation of soluble immunoglobulin aggregates by mouse mononuclear phagocytesâ€"Stimulation by colony-stimulating factor. Cellular Immunology, 1982, 73, 98-105.	1.4	4
567	Specific antibody uptake in tuberculosis?. European Journal of Nuclear Medicine and Molecular Imaging, 1993, 20, 568-569.	2.2	4
568	Recurrent Erysipelas or Erysipelas-like Rash?. Clinical Infectious Diseases, 1996, 22, 881-881.	2.9	4
569	Selecting outcome parameters in studies aimed at improving rational use of antibiotics - practical considerations. Journal of Clinical Pharmacy and Therapeutics, 2003, 28, 475-478.	0.7	4
570	Leptin and proinflammatory cytokines in patients undergoing peritoneal dialysis. European Journal of Clinical Investigation, 2003, 33, 525-526.	1.7	4
571	Response to Gil et al.: Toll-like receptor-2 – an important component of host defense. Trends in Microbiology, 2005, 13, 299-300.	3.5	4
572	Validity, reliability and feasibility of a new observation rating tool and a post encounter rating tool for the assessment of clinical reasoning skills of medical students during their internal medicine clerkship: a pilot study. BMC Medical Education, 2020, 20, 198.	1.0	4
573	Non-LPS components of Chlamydia pneumoniae stimulate cytokine production through Toll-like receptor 2-dependent pathways. European Journal of Immunology, 2002, 32, 1188-1195.	1.6	4
574	Cell surface characteristics and DNA content of macrophages in murine bone marrow cultures. Histochemistry, 1987, 86, 433-436.	1.9	3
575	Relapsing hepatitis due to cytomegalovirus?. Journal of Infection, 1991, 23, 175-178.	1.7	3
576	Serial indium-111-labelled IgG biodistribution in ratPneumocystis carinii pneumonia: a tool to monitor the course and severity of the infection. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 1129-1132.	2.2	3

#	Article	IF	CITATIONS
577	An unusual case of severe combined immunodeficiency with hypereosinophilia. Journal of Internal Medicine, 1997, 242, 267-269.	2.7	3
578	Reply to: Chronic fatigue syndrome: a clinical and laboratory study with a well-matched control group. Journal of Internal Medicine, 2004, 256, 268-269.	2.7	3
579	Anti-TNF therapy and plasma HDL cholesterol concentration. Atherosclerosis, 2005, 182, 375.	0.4	3
580	Letter to the Editor: The experience of fatigue in the brain. Psychological Medicine, 2009, 39, 523-524.	2.7	3
581	Comment on "Power of Rare Diseases: Found in Translation― Science Translational Medicine, 2014, 6, 219le1.	5.8	3
582	Growth on Carbohydrates from Carbonaceous Meteorites Alters the Immunogenicity of Environment-Derived Bacterial Pathogens. Astrobiology, 2020, 20, 1353-1362.	1.5	3
583	Pro-Inflammatory Cytokine Response in Acute Infection. Advances in Experimental Medicine and Biology, 2003, 531, 229-240.	0.8	3
584	Pathogenesis of Fever: Are Circulating Pyrogenic Cytokines the Only Mediators?. Clinical Infectious Diseases, 1998, 26, 1479-1479.	2.9	2
585	THE INFLUENCE OF DIETARY FISH-OIL SUPPLEMENTATION ON CUTANEOUS LEISHMANIA AMAZONENSIS INFECTION IN MICE. Cytokine, 2002, 19, 213-217.	1.4	2
586	Defective acute inflammation in Crohn's disease. Lancet, The, 2006, 368, 577-578.	6.3	2
587	To the Editor. European Journal of Immunology, 2006, 36, 2817-2818.	1.6	2
588	Influence of innate cytokine production capacity on clinical manifestation and severity of pediatric meningococcal disease. Critical Care Medicine, 2009, 37, 2812-2818.	0.4	2
589	Mevalonate kinase deficiency nomenclature. Rheumatology International, 2014, 34, 295-296.	1.5	2
590	Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Annals of Internal Medicine, 2015, 163, 885.	2.0	2
591	Can we Tackle the Antibiotic Threat?. European Review, 2016, 24, 49-62.	0.4	2
592	Familial Autoinflammatory Syndromes. , 2017, , 1666-1684.e4.		2
593	A possible link between recurrent upper respiratory tract infections and lower cytokine production in patients with Q fever fatigue syndrome. European Journal of Immunology, 2019, 49, 1015-1022.	1.6	2
594	Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells., 2000, 30, 541.		2

#	Article	IF	Citations
595	Giant chalazia in the hyperimmunoglobulinemia E (hyper-lgE) syndrome. European Journal of Ophthalmology, 2004, 14, 258-260.	0.7	2
596	Introduction: Cytokines in the biotherapy of infectious diseases. Biotherapy (Dordrecht, Netherlands), 1994, 7, 149-150.	0.7	1
597	Act now on antibiotic resistance. Nature Medicine, 1998, 4, 985-985.	15.2	1
598	Chemical Sensitivity in Symptomatic Cambodia Veterans. Archives of Environmental Health, 2003, 58, 740-745.	0.4	1
599	Inflammatory responses to infection: The Dutch contribution. Immunology Letters, 2014, 162, 113-120.	1.1	1
600	Reply to Raoult. Clinical Infectious Diseases, 2017, 65, 1055-1056.	2.9	1
601	Cytokine signature in chronic fatigue syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9435-E9435.	3.3	1
602	Systemic Autoinflammatory Syndromes. , 2019, , 825-834.e1.		1
603	Lethal Escherichia coli and Salmonella typhimurium endotoxemia is mediated through different pathways. European Journal of Immunology, 2001, 31, 2529.	1.6	1
604	NOD2 engagement induces proinflammatory cytokine production, but not apoptosis, in leukocytes isolated from patients with Crohn's disease. European Cytokine Network, 2008, 19, 185-9.	1.1	1
605	The place of quinolones in the treatment of respiratory tract infections. Pharmaceutisch Weekblad, 1989, 11, 132-133.	0.7	0
606	Treatment of Otitis Media. Clinical Infectious Diseases, 1995, 21, 1069-1069.	2.9	0
607	Macrophage targeting in experimental arthritis. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 727-727.	2.2	0
608	International experts recommend concerted attack against infection. Lancet, The, 1997, 349, 184.	6.3	0
609	Whole-blood cultures: a valid and reliable tool for studying cytokines in exercise. European Journal of Clinical Investigation, 1999, 29, 182-183.	1.7	0
610	Physical activity and exercise performance in symptomatic Cambodia veterans. QJM - Monthly Journal of the Association of Physicians, 2002, 95, 99-105.	0.2	0
611	Failure of prescribers to adjust antibiotic dose to impaired renal function in daily clinical practice. British Journal of Clinical Pharmacology, 2002, 53, 557P-557P.	1.1	O
612	Dr Baschetti rides/writes again. European Journal of Clinical Investigation, 2004, 34, 317-317.	1.7	0

#	Article	IF	CITATIONS
613	Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolemia. European Journal of Clinical Investigation 2004;34:94-99. European Journal of Clinical Investigation, 2004, 34, 322-322.	1.7	0
614	Erratum to Letter to the Editor: "Anti-TNF therapy and plasma HDL cholesterol concentration― [Atherosclerosis 182 (2005) 375]. Atherosclerosis, 2006, 184, 458.	0.4	O
615	Response to "Schnitzler's Syndrome: A True Auto-Inflammatory Disorder?― Seminars in Arthritis and Rheumatism, 2008, 38, 164.	1.6	O
616	Letter to the Editor: Chronic fatigue in Gulf War veterans: should it be treated as chronic fatigue syndrome?. Psychological Medicine, 2009, 39, 1401-1402.	2.7	O
617	Reply: Change in grey matter volume cannot be assumed to be due to cognitive behavioural therapy. Brain, 2009, 132, e120-e120.	3.7	O
618	Reply to: can CBT substantially change grey matter volume in chronic fatigue syndrome?. Brain, 2009, 132, e111-e111.	3.7	0
619	Caspase-1, but not ASC or NLRP3 inflammasome components, mediates IL-1beta activation and antifungal defense in disseminated candidiasis. Cytokine, 2009, 48, 120.	1.4	O
620	PS2-102. Cross-tolerance and priming between C-type lectin receptors and TLRs. Cytokine, 2011, 56, 92-93.	1.4	O
621	Vermeer and Leeuwenhoek, Figments of the Imagination?. FASEB Journal, 2012, 26, 2238-2238.	0.2	O
622	Resistance after selective decontamination. Lancet Infectious Diseases, The, 2012, 12, 179.	4.6	0
623	Selective digestive decontamination and bacterial resistance – Authors' reply. Lancet Infectious Diseases, The, 2013, 13, 738-739.	4.6	O
624	Cytokine Inhibition in Patients With Chronic Fatigue Syndrome. Annals of Internal Medicine, 2017, 167, 448.	2.0	0
625	Decontamination of Oral or Digestive Tract for Patients in the Intensive Care Unit. JAMA - Journal of the American Medical Association, 2018, 320, 2081.	3.8	O
626	Required Actions to Control Antimicrobial Resistant Healthcare-Associated Infections., 2012, , 183-202.		0
627	Infecties bij patiënten met een gestoorde afweer. , 2016, , 331-348.		O
628	50 years Netherlands Journal of Medicine - 2002, reshaping the journal. Netherlands Journal of Medicine, 2008, 66, 398-9.	0.6	0